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Abstract
Obesity is associated with a range of health outcomes that are of clinical and public health 
significance, including cancer. Herein, we summarize epidemiologic and preclinical evidence for 
an association between obesity and increased risk of breast and prostate cancer incidence and 
mortality. Moreover, we describe data from observational studies of weight change in humans and 
from calorie restriction studies in mouse models which support a potential role for weight loss in 
counteracting tumor-promoting properties of obesity in breast and prostate cancers. Given that 
weight loss is challenging to achieve and maintain, we also consider evidence linking treatments 
for obesity-associated co-morbidities, including metformin, statins and non-steroidal anti-
inflammatory drugs, with reduced breast and prostate cancer incidence and mortality. Finally, we 
highlight several challenges that should be considered when conducting epidemiologic and 
preclinical research in the area of obesity and cancer, including the measurement of obesity in 
population-based studies, the timing of obesity and weight change in relation to tumor latency and 
cancer diagnosis, and the heterogeneous nature of obesity and its associated co-morbidities. Given 
that obesity is a complex trait, comprised of behavioral, epidemiologic and molecular/metabolic 
factors, we argue that a transdisciplinary approach is the key to understanding the mechanisms 
linking obesity and cancer. As such, this review highlights the critical need to integrate evidence 
from both epidemiologic and preclinical studies to gain insight into both biologic and non-biologic 
mechanisms contributing to the obesity-cancer link.
Keywords
aspirin; breast cancer; cholesterol; epidemiology; insulin; prostate cancer; mechanisms; 
metformin; mouse models; NSAIDs; obesity; screening; statins; transdisciplinary; weight loss
Corresponding author: Dr. Emma H. Allott, Department of Epidemiology, CB 7435, University of North Carolina at Chapel Hill, 135 
Dauer Drive, Chapel Hill, NC 27599, USA. Phone: +1 919-843-0441; Fax: +1 919-966-2089; allott@email.unc.edu. 




Endocr Relat Cancer. Author manuscript; available in PMC 2016 December 01.
Published in final edited form as:














Cancer is predicted to overtake heart disease as the leading cause of death across all age 
groups in the US by 2030, translating to a 45% increase in the number of cancer diagnoses 
in the next 15 years (American Society of Clinical Oncology 2014). Global obesity 
prevalence has been increasing by approximately half a body mass index (BMI) unit per 
decade over the past three decades, resulting in over 600 million adults worldwide with a 
BMI of 30 kg/m2 or greater (Finucane, et al. 2011; Stevens, et al. 2012). With more than one 
in three US adults classified as obese, the prevalence of obesity in the US is currently the 
highest in the Western world (Finucane et al. 2011; Ogden, et al. 2014).
Obesity is associated with increased risk of a variety of different cancer types (World 
Cancer Research Fund 2007). Of these obesity-associated cancer types, almost 13% of 
incident cases worldwide, and approximately 20% of incident cases in Europe and North 
America, are attributable to obesity (Arnold, et al. 2014). Furthermore, it is estimated that 
one quarter of these cases could have been avoided had the worldwide obesity prevalence 
not approximately doubled since 1980 (Arnold, et al. 2014). Overweight and obesity also 
drive cancer progression, and have been estimated to account for 14% of all cancer deaths in 
men and 20% in women in the United States (Calle, et al. 2003), while approximately 6% of 
cancer deaths around the same time period in Europe were attributable to obesity (Banegas, 
et al. 2003).
Cancers of the breast and prostate are among the most commonly diagnosed and among the 
leading causes of cancer deaths in women and men, respectively, both in the US and 
worldwide (Jemal, et al. 2011; Siegel, et al. 2013). Therefore, understanding mechanisms 
linking obesity and risk of these common tumor types will be important for cancer 
prevention efforts worldwide. In addition, of over 11 million US individuals living with 
cancer, survivors of breast cancer constitute the largest group (22%), followed by survivors 
of prostate cancer (19%) (Centers for Disease Control & Prevention 2011). Therefore, 
understanding mechanisms linking obesity and cancer progression in these common tumor 
types has great importance for a large proportion of cancer survivors, and will likely also 
benefit survivors of other obesity-associated cancer types. Molecular mechanisms linking 
obesity and cancer have been reviewed in depth elsewhere (Allott, et al. 2013b; Ford, et al. 
2013a; Lashinger, et al. 2014a). As such, this review adopts a transdisciplinary approach, 
summarizing findings from both epidemiologic and preclinical studies (Figure 1), in 
addition to examining evidence for the modifiable nature of obesity and related co-
morbidities through weight loss and pharmacologic interventions in both humans and mouse 
models. Finally, we consider how a transdisciplinary approach can minimize the weaknesses 
and maximize the strengths of each discipline, enabling a deeper understanding of 
mechanisms linking obesity and cancer.
2. Transdisciplinary insights into associations between obesity and cancer
i. Obesity and breast cancer
The association between obesity and breast cancer risk is complex, varying by menopausal 
status and by breast cancer subtype. Obesity is associated with reduced breast cancer 
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incidence in premenopausal women (World Cancer Research Fund 2007), but increased 
breast cancer incidence in postmenopausal women (Munsell, et al. 2014; World Cancer 
Research Fund 2007), although the association with postmenopausal breast cancer is 
attenuated in women using hormone replacement therapy (Munsell et al. 2014). While these 
contrasting associations by menopausal status are consistently reported, differences in these 
associations by hormone receptor status are less well understood. Within postmenopausal 
breast cancers, there is a suggestion that the association with obesity is strongest among 
hormone receptor-positive cases (Althuis, et al. 2004; Canchola, et al. 2012; Rosenberg, et 
al. 2006; Suzuki, et al. 2009), although other studies did not find differences in these 
associations by breast cancer subtype (Millikan, et al. 2008; Phipps, et al. 2008; Yang, et al. 
2011). Several studies have reported that, although obesity is a protective factor for total 
premenopausal breast cancer, it is associated with increased risk of triple negative and basal-
like disease in premenopausal women (Gaudet, et al. 2011; Millikan et al. 2008; Yang et al. 
2011). Interestingly, some evidence suggests that obesity may be a risk factor for basal-like 
breast cancer regardless of menopausal status (Millikan et al. 2008), suggesting a role for 
non-hormonal mechanisms in basal-like breast cancer pathogenesis.
While the association between obesity and breast cancer risk differs by menopausal status, 
obesity is associated with increased risk of breast cancer recurrence and mortality in both 
pre and postmenopausal women (Chan, et al. 2014; Niraula, et al. 2012). While several 
studies have suggested that this association may be stronger among women with hormone 
receptor-positive tumors (Azrad and Demark-Wahnefried 2014; Jiralerspong, et al. 2013; 
Sparano, et al. 2012; Tait, et al. 2014), others reported no difference in the association 
between obesity and breast cancer-specific mortality by subtype (Niraula et al. 2012; Phipps 
et al. 2008). However, partial availability of subtype data and lower numbers of patients 
with rarer breast cancer subtypes is a limitation for many studies (Althuis et al. 2004). Given 
evidence for etiologic heterogeneity of breast cancer, understanding the obesity-breast 
cancer link in humans requires large, well-annotated studies with sufficient power to 
conduct stratified analysis both by menopausal status and subtype.
The recognition of breast cancer as a heterogeneous disease has led to the characterization of 
mouse models which reflect human breast cancer subtypes (Herschkowitz, et al. 2007). One 
particular challenge of preclinical models of breast cancer is that estrogen receptor (ER) is 
weakly expressed in most mouse mammary tumors, particularly in genetically-engineered 
mice, and thus murine models of hormone receptor-positive breast cancer may not be fully 
representative of human luminal breast cancer (Borowsky 2011; Herschkowitz et al. 2007). 
Nonetheless, diet-induced obesity has been demonstrated to drive tumor growth in a variety 
of mouse models with both luminal (Ford, et al. 2013b; Pape-Ansorge, et al. 2002) and 
basal-like tumor characteristics (Dogan, et al. 2007; Dunlap, et al. 2012; Giles, et al. 2012; 
Hakkak, et al. 2007; Nogueira, et al. 2012; Sundaram, et al. 2013), lending support to 
epidemiologic observations. In contrast, there is little preclinical support for links between 
obesity and luminal B or HER-2 breast cancer subtypes (Cleary, et al. 2004; Ford, et al. 
2013b), although the degree to which these models are representative of these human 
subtypes is unclear. Finally, one study showed that diet-induced obesity enhanced the 
growth of luminal-like tumors in ovariectomized mice, but not in mice with intact ovaries 
(Nunez, et al. 2008), suggesting that the relationship between obesity and postmenopausal 
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luminal breast cancer should be tested in ovariectomized mice in order to model the human 
postmenopausal environment. However, given epidemiologic evidence supporting an 
association between obesity and basal-like breast cancer regardless of menopausal status, the 
relevance of ovariectomization to study the impact of diet-induced obesity on basal-like 
breast cancer in mouse models is less clear.
ii. Obesity and prostate cancer
Although individual studies are conflicted regarding the association between obesity and 
prostate cancer risk, a number of large meta-analyses have reported that obesity is associated 
with a modestly elevated total prostate cancer incidence (Bergstrom, et al. 2001; Hu, et al. 
2014; MacInnis and English 2006; Renehan, et al. 2008). One meta-analysis demonstrated 
that findings from the individual contributing studies differed by geographic region 
(Renehan et al. 2008), thereby offering insight into these somewhat conflicted results. 
Prostate specific antigen (PSA) levels are reduced in obese men via hemodilution (Banez, et 
al. 2007), thereby lowering the likelihood of a PSA-driven biopsy and giving rise to an 
obesity-associated detection bias. This bias becomes apparent when comparing the results of 
US studies where PSA screening is widespread, with the results of European studies where 
PSA screening is less common (Renehan et al. 2008). In the US, where prostate biopsies are 
largely driven by PSA screening, obese men have a reduced chance of undergoing biopsy 
compared to normal weight men, leading to the detection of fewer cancers in obese 
individuals and biasing the association between obesity and prostate cancer towards the null. 
In countries with lower PSA screening rates, such as Europe and Australia, this detection 
bias is reduced and meta-analysis of studies from these regions demonstrates a positive 
association between obesity and prostate cancer risk (Renehan et al. 2008). These data 
highlight the importance of considering how the association between obesity and prostate 
cancer risk is impacted by mode of cancer detection, particularly in the context of changing 
PSA screening recommendations in the US (Moyer and U.S. Preventative Services Task 
Force 2012).
While the association between obesity and total prostate cancer is complicated by obesity-
associated detection bias, there is consistent and convincing evidence for an association 
between obesity and elevated risk of aggressive prostate cancer (Rodriguez, et al. 2007; 
Zhang, et al. 2015). Furthermore, multiple large studies, both before and after the 
introduction of widespread PSA screening in the US, demonstrated an association between 
obesity and increased prostate cancer-specific mortality (Andersson, et al. 1997; Cao and 
Ma 2011; Rodriguez, et al. 2001; Wright, et al. 2007; Zhang et al. 2015), indicating that 
obesity-associated detection bias does not completely explain the association between 
obesity and prostate cancer, but that biologic mechanisms must also play a role.
Consistent with epidemiologic evidence for an association between obesity and tumor 
aggressiveness and progression, tumor growth in mouse models of prostate cancer has been 
shown to be responsive to obesity. A number of studies have demonstrated a role for diet-
induced obesity in promoting prostate tumor growth in the transgenic adenocarcinoma of the 
prostate (TRAMP) mouse model (Bonorden, et al. 2012; Llaverias, et al. 2010). In addition, 
diet-induced obesity reduced tumor latency in the Hi-Myc mouse model, via increased Akt/
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mTOR signaling (Blando, et al. 2011; Kobayashi, et al. 2008), and promoted tumor 
progression in a transgenic mouse model with PTEN haploinsufficiency, via increased 
inflammatory and insulin signaling pathways (Liu, et al. 2015). These transgenic models 
may have relevance to human prostate cancer given that Myc copy number is amplified in 
up to one third of human prostate cancers (Ellwood-Yen, et al. 2003) and PTEN loss is the 
most common genetic alteration in human prostate cancer (Wang, et al. 2003).
3. Non-biologic mechanisms contributing to the obesity - cancer link
i. Obesity and cancer screening
Evidence suggests that obesity-associated screening and detection biases may act to delay 
cancer diagnosis, thereby increasing cancer-specific mortality in obese patients (Figure 2). 
Obese individuals may be less likely to participate in screening programs which could 
contribute to delayed cancer diagnosis, an association shown to be modified by the type of 
screening test, by race and by gender (Fagan, et al. 2011). Indeed, mammography screening 
rates are reduced by as much as 10% in obese (BMI ≥ 30 kg/m2) and 20% in morbidly obese 
(BMI ≥ 40 kg/m2) women (Maruthur, et al. 2009) and while the reasons for reduced 
participation in cancer screening are not completely understood, they may include modesty, 
pain, and/or competing healthcare demands (Friedman, et al. 2012).
In contrast to associations with breast cancer screening, an inverse association between 
obesity and PSA screening frequency has been reported in prostate cancer, with obese men 
being screened more frequently than their normal weight counterparts (Scales, et al. 2007). 
However, obesity is associated with reduced likelihood of prostate cancer diagnosis in a 
screened population despite higher PSA screening frequency in obese men, suggesting that 
obesity may decrease screening effectiveness in some cancer types. In obese prostate cancer 
patients, their larger body size and bigger prostate make conducting a digital rectal exam 
more challenging (Chu, et al. 2011), and a large prostate may reduce the likelihood of 
finding the cancer at biopsy (Freedland, et al. 2006). This is also true for other cancer types; 
mammography is anecdotally more difficult in obese patients (Amy, et al. 2006), potentially 
delaying cancer diagnosis even in screened obese individuals. Indeed, obesity has been 
associated with higher stage at breast cancer diagnosis (Cui, et al. 2002), suggesting that 
obese women may be diagnosed later in the course of their disease. However, another study 
reported this finding regardless of mammography screening frequency, suggesting that the 
association between obesity and high stage breast cancer may not simply be a result of lower 
screening rates in this population (Kerlikowske, et al. 2008), but that biologic mechanisms 
must also play a role.
Finally, the larger blood volume in obese individuals has been associated with biomarker 
hemodilution, as has been suggested in PSA-detected prostate cancer (Banez et al. 2007). 
Several studies have estimated that PSA levels are reduced by approximately 15% in cancer-
free morbidly obese (BMI ≥ 35 kg/m2) men, while PSA mass (i.e. the absolute quantity of 
PSA in the blood) is not associated with obesity status (Grubb, et al. 2009; Rundle and 
Neugut 2009). Lower biomarker levels in obesity reduce the likelihood of reaching biopsy 
thresholds, potentially contributing to delayed diagnosis in obese individuals.
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ii. Obesity and cancer treatment
In addition to biologic mechanisms [reviewed in (Lashinger, et al. 2014b)], non-biologic 
factors also contribute to reduced treatment efficacy in obese patients (Figure 2). There is 
considerable evidence to suggest that obese cancer patients are undertreated with systemic 
therapies (Lyman and Sparreboom 2013), and this may negatively impact cancer outcomes. 
Traditionally, chemotherapy dosing is based upon the body surface area (BSA) of the 
patient. However, there is uncertainty regarding dosing of obese patients and evidence that 
dose reduction occurs in this population, either because an idealized body weight is used to 
calculate BSA, or because BSA is arbitrarily capped due to toxicity concerns (Lyman, et al. 
2003). Current clinical guidelines for chemotherapy dosing in obese patients indicate that 
weight-based chemotherapy doses should be given and that dose should not be reduced for 
obese patients (Griggs, et al. 2012). As such, it is recommended that any modifications to 
dose due to toxicity concerns or presence of co-morbidities should be made independent of 
the patient's obesity status (Lyman and Sparreboom 2013).
In prostate cancer, obesity is associated with increased daily prostate shift, rendering 
external beam radiation treatment more technically challenging, and potentially contributing 
to increased rates of treatment failure in obese patients (Merrick, et al. 2007). Technical 
difficulties applying the adequate radiation dose to the correct area in obese patients has also 
been suggested in breast cancer (Carmichael and Bates 2004). In addition to these potential 
difficulties with radiation therapy, obese patients may also be less likely to make good 
surgical candidates. In prostate cancer, obesity has been shown to be associated with 
capsular incision, reflecting a less-than-ideal operation (Freedland, et al. 2005). However, 
even when focusing solely on patients with organ-confined disease and negative surgical 
margins, obesity remains associated with biochemical recurrence following radical 
prostatectomy, implying that obesity is associated with disease progression in prostate 
cancer through mechanisms other than how it may affect surgical technique (Freedland, et 
al. 2004).
Obesity and related co-morbidities are associated with increased risk of adverse treatment 
effects, which may impact the treatment plan (Schmitz, et al. 2013). In breast cancer, obesity 
has been associated with a higher risk of lymphedema, in addition to other treatment-related 
side effects (Togawa, et al. 2014). Obese, diabetic breast cancer patients undergoing 
chemotherapy have increased likelihood of side effects including infection and 
chemotherapy-related toxicity (Srokowski, et al. 2009). In addition, cytotoxic therapy has 
been associated with treatment-related weight gain and metabolic syndrome in breast cancer 
patients (Bicakli, et al. 2014; Makari-Judson, et al. 2014), potentially exacerbating these 
aforementioned side effects. In prostate cancer, obesity is associated with weight gain and 
increased risk of diabetes following androgen deprivation therapy (Keto, et al. 2011; Tsai, et 
al. 2014), particularly among older men (Morgans, et al. 2014). Given that more men 
diagnosed with prostate cancer die from cardiovascular disease than from prostate cancer 
(Allott et al. 2013b), this relationship has important implications for prostate cancer 
survivors.
Finally, excess body weight has been linked to altered metabolism of cytotoxic drugs and 
therapies, potentially via a number of mechanisms including altered levels of circulating 
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growth factors, hormones and cytokines (Litton, et al. 2008; Rodvold, et al. 1988). Despite 
evidence that aromatase inhibitors may not be as efficacious in obese breast cancer patients 
(Azrad and Demark-Wahnefried 2014; Ioannides, et al. 2014; Wolters, et al. 2012), standard 
doses are given irrespective of BSA or body size (Goodwin and Pritchard 2010). In contrast, 
response to tamoxifen has not been shown to differ by obesity status (Wolters et al. 2012), 
and no differences in ER-positive breast cancer recurrence rates by obesity status have been 
reported following tamoxifen treatment (Dignam, et al. 2003). Finally, one trial suggested 
that obese breast cancer patients treated with chemotherapy had reduced disease-free 
survival relative to normal weight patients, even after controlling for other prognostic factors 
(de Azambuja, et al. 2010). In prostate cancer, obesity at the time of androgen deprivation 
therapy is associated with increased risk of castrate-resistant prostate cancer, metastasis, and 
prostate cancer-specific mortality (Keto et al. 2011). Although the exact explanation for this 
is unclear, one study found that testosterone levels in obese men on androgen deprivation 
therapy were higher, suggesting inadequate testosterone suppression (Smith 2007). It has 
been hypothesized that this may be because the amount of gonadotropin-releasing hormone 
analogue given is the same regardless of BSA, and thus obese men may be under dosed. 
However, while these non-biological factors must be considered, they cannot completely 
explain the association between obesity and cancer mortality, and biologic mechanisms also 
contribute (Lashinger et al. 2014b).
4. Obesity and related co-morbidities as modifiable lifestyle factors
i. Weight gain and loss
Evidence for the association between obesity and cancer is substantiated by studies showing 
that weight change can impact both risk and survival for obesity-associated cancers (Figure 
3). Bariatric procedures to cause weight loss have been associated with reduced risk of 
obesity-associated cancer types and a 40-50% decrease in cancer-specific mortality across 
cancer types (Adams, et al. 2009; Sjostrom, et al. 2007), suggesting that weight loss may be 
an effective chemopreventive strategy in obese individuals (Ashrafian, et al. 2011). 
Interestingly, one prospective intervention trial suggested that bariatric procedures may be 
more effective at decreasing cancer risk in women, compared to men (Sjostrom, et al. 2009), 
although these results should be interpreted with caution given the smaller sample size of 
males and mean follow-up time of only one decade, which may not be a long enough latency 
period for certain cancer types to manifest (Renehan 2009). Aside from these studies of 
bariatric patients, the majority of evidence supporting a role for weight change in breast 
cancer incidence and mortality comes from secondary analyses of observational studies. Of 
note, the most common pattern of weight change over time is consistent weight gain 
throughout adulthood (Harvie, et al. 2005), and therefore statistical power to study the 
impact of weight loss is often limited.
Adult weight gain is associated with increased risk of postmenopausal breast cancer 
(Eliassen, et al. 2006), with a suggestion of a stronger association for hormone receptor-
positive breast cancer (Eliassen et al. 2006; Vrieling, et al. 2010). Furthermore, adult weight 
gain prior to diagnosis is associated with increased mortality from postmenopausal breast 
cancer (Cleveland, et al. 2007). Conversely, weight loss during adulthood, whether before or 
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after menopause, has been associated with decreased risk of postmenopausal breast cancer 
(Eliassen et al. 2006; Harvie et al. 2005), again with the strongest inverse associations for 
hormone receptor-positive breast cancer (Eliassen et al. 2006). While clinical trials to 
formally examine the impact of weight loss on breast cancer-specific mortality have not yet 
been conducted, two trials in breast cancer survivors reported that weight loss of >10% of 
body mass can be achieved in this population (Befort, et al. 2012; Goodwin, et al. 2014). 
Furthermore, a weight loss intervention in cancer-free postmenopausal women suggested 
that 10% weight loss is sufficient to positively impact biomarker levels associated with 
breast cancer in both serum and benign breast tissue (Fabian, et al. 2013), indicating that 
such an intervention may be both feasible and worthwhile (Irwin 2014).
Evidence from mouse models of breast cancer showing that weight loss impacts tumor 
growth supports these epidemiologic data. Weight loss can be achieved in mouse models by 
calorie restriction (CR), a 20-40% reduction in total energy intake relative to a control group 
fed ad libitum, arguably one of the most potent dietary regimens for suppressing 
carcinogenesis (Hursting, et al. 2010). Despite the suggestion of stronger epidemiologic 
associations between weight change and hormone receptor-positive breast cancer, CR slows 
tumor growth in mouse models regardless of tumor subtype (Dunlap et al. 2012; Ford et al. 
2013b; Mizuno, et al. 2013; Nogueira et al. 2012; Pape-Ansorge et al. 2002), providing 
rationale to study the impact of weight loss across breast cancer subtypes in humans. 
Mechanistic insights from these models have highlighted Akt/mTOR signaling and the 
insulin/insulin-like growth factor (IGF) 1 axis as two pro-tumor pathways upregulated by 
obesity and reversed by CR (Hursting et al. 2010). Interestingly, a protective effect of 
intermittent CR on tumor growth has also been reported (Rogozina, et al. 2013), and this 
dietary regimen may be more feasible and appealing to humans. While the majority of 
preclinical studies randomize mice to CR from the outset, two preclinical studies have 
specifically tested the impact of diet-induced obesity followed by weight loss, by 
incorporating a diet switch during the intervention period. Interestingly, these studies 
reported contrasting findings, with one reporting that weight loss reversed the tumor-
promoting effect of obesity (Sundaram, et al. 2014b), and the other reporting the weight loss 
did not impact obesity-fueled tumor growth (De Angel, et al. 2013). Key differences 
between studies included the degree of obesity attained by the mice and the timing and 
duration of weight loss, in addition to the use of two different mouse models of basal-like 
breast cancer, one xenograft (De Angel et al. 2013) and the other transgenic (Sundaram et al. 
2014b). Discrepant findings such as these may shed light on mechanisms linking weight loss 
and breast cancer, in addition to informing future study design in both preclinical mouse 
models and humans.
Retrospective analyses of large cohort studies have also revealed inverse associations 
between weight loss and prostate cancer incidence and mortality. Relative to weight 
maintenance, adult weight gain is associated with increased risk of aggressive prostate 
cancer (Bassett, et al. 2011), while adult weight loss is associated with reduced risk of 
aggressive prostate cancer (Rodriguez et al. 2007). Furthermore, some large prospective 
cohort studies have reported that weight gain in adulthood is associated with increased 
prostate cancer-specific mortality (Bassett et al. 2011; Wright et al. 2007), although others 
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reported no association between adult weight change and prostate cancer-specific mortality 
(Chamberlain, et al. 2011; Moller, et al. 2013). Studies focused on weight change within the 
decade of prostate cancer diagnosis report more consistent findings, with weight gain in the 
five year time period preceding diagnosis associated with increased risk of recurrence 
(Joshu, et al. 2011; Whitley, et al. 2011), and weight gain in the five year time period 
following diagnosis associated with increased risk of prostate cancer-specific mortality 
(Bonn, et al. 2014).
While evidence for a role for weight loss in counteracting tumor growth in mouse models of 
prostate cancer is relatively sparse, a tumor-inhibitory effect of CR has been demonstrated 
via reduced insulin/IGF1 levels and increased tumor apoptosis in a xenograft mouse model 
(Galet, et al. 2013), although this effect has not been reported in all xenograft models 
(Buschemeyer, et al. 2010; Thomas, et al. 2010). In addition, one study demonstrated that 
CR slowed progression to adenocarcinoma in the Hi-Myc transgenic mouse model of 
prostate cancer, via reduced prostate inflammation and inhibition of Akt/mTOR signaling 
(Blando et al. 2011). CR has also been demonstrated to impact tumor growth in the TRAMP 
model, with intermittent CR having a greater impact than chronic CR (Bonorden, et al. 
2009), although a role for intermittent CR has not been supported by other prostate cancer 
studies (Buschemeyer et al. 2010; Thomas et al. 2010).
Given the challenges surrounding compliance with CR and maintenance of weight loss in 
humans, alternative strategies are also worth exploring. Intermittent CR is one such strategy, 
and while one randomized weight loss trial in women showed that both intermittent and 
chronic CR caused weight loss and improved insulin sensitivity and cytokine profile 
(Harvie, et al. 2011), avoiding weight gain may remain the most sensible approach both for 
general health in addition to chemoprevention (Thompson and McTiernan 2011). 
Alternatively, understanding the mechanisms by which CR increases tumor latency and 
slows tumor progression may help to identify CR mimetics with chemopreventive properties 
[reviewed in (Hursting et al. 2010)].
ii. Pharmaceuticals
a. Type II diabetes and metformin—Type II diabetes currently affects approximately 
15% of the adult population in the US, and the prevalence of this obesity-associated co-
morbidity is on the increase (Boyle, et al. 2010). Epidemiologic data support an association 
between diabetes and increased risk of certain cancer types, including breast cancer (De 
Bruijn, et al. 2013; Giovannucci, et al. 2010; Larsson, et al. 2007; Tsilidis, et al. 2015b). 
Although not all studies have reported subtype-specific differences in this association 
(Campos-Gomez, et al. 2014), there is some evidence that the association between diabetes 
and breast cancer risk may be stronger in postmenopausal women (Larsson et al. 2007; 
Michels, et al. 2003) and for hormone receptor-positive breast cancer (Michels et al. 2003). 
In addition, a meta-analysis of clinical trials and prospective cohort studies reported that 
diabetes is associated with increased breast cancer-specific mortality, although subtype was 
not examined (De Bruijn et al. 2013). In direct contrast to the positive association with 
breast cancer risk, there is an inverse association between diabetes and total prostate cancer 
incidence (Kasper and Giovannucci 2006; Zhang, et al. 2012). Temporal analysis has 
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demonstrated that longer duration of diabetes is more protective for total prostate cancer risk 
(Kasper, et al. 2009; Tsilidis, et al. 2015a), suggesting that the metabolic and hormonal 
environment of advanced/end stage diabetes, characterized by reduced bioavailable 
testosterone and low insulin, is consistent with protection from total prostate cancer 
incidence (Allott, et al. 2013a; Kasper and Giovannucci 2006). However, longer duration of 
diabetes in obese men was associated with increased risk of metastasis following radical 
prostatectomy (Wu, et al. 2013), and diabetes has been associated with increased risk of 
prostate cancer-specific mortality (Cai, et al. 2014), suggesting that the low insulin 
environment of advanced diabetes may select for more aggressive prostate cancers which 
can survive in this environment (Allott et al. 2013a). Therefore, while associations with 
diabetes are contrasting for breast and prostate cancer incidence, associations with cancer 
progression and mortality are consistent for both tumor types.
Relative to other anti-diabetic therapies, metformin has been associated with reduced total 
cancer incidence in some (Decensi, et al. 2010; Evans, et al. 2005), but not all studies 
(Tsilidis, et al. 2014), and with decreased cancer-specific mortality (Currie, et al. 2012, 
Lega, et al 2014). In line with these findings, evidence supporting a role for metformin in 
breast cancer is somewhat mixed. A meta-analysis reported that metformin use was 
associated with reduced breast cancer incidence and mortality (Zhang, et al. 2013), but other 
studies failed to demonstrate a protective effect of metformin on breast cancer incidence 
(Franciosi, et al. 2013; Kowall, et al. 2015; Tsilidis, et al. 2014) or mortality (Lega, et al. 
2014). Furthermore, there is inconsistent evidence for differences in these associations by 
breast cancer subtype, with one study reporting a larger proportion of progesterone receptor-
positive tumors in metformin users versus non-users (Berstein, et al. 2011), while another 
study did not find any difference in the frequency of hormone receptor-positive tumors by 
metformin use (Besic, et al. 2014). A trial in which women were randomized to metformin 
one month prior to breast cancer surgery found that metformin use reduced Ki67 expression 
in HER2-positive resected tumors (DeCensi, et al. 2014), while another study reported that 
metformin use was associated with reduced HER2-positive breast cancer-specific mortality 
(He, et al. 2012). In support of these epidemiologic data, preclinical data show that 
metformin suppressed overexpression of the HER2 protein via Akt/mTOR pathway 
inhibition (Vazquez-Martin, et al. 2009), and delayed the onset of adenocarcinoma in a 
transgenic mouse model of HER2-positive breast cancer (Anisimov, et al. 2010). However, 
metformin has also been shown to slow tumor growth in an ER-positive mouse model of 
breast cancer, via suppression of obesity-associated adipokine levels and reduced Akt/
mTOR pathway activation (Fuentes-Mattei, et al. 2014), suggesting that the potential 
chemopreventive effect of metformin may not be limited to HER2-positive tumors. Finally, 
a preclinical study reported that metformin does not impact tumor growth in nondiabetic rat 
and mouse models (Thompson, et al. 2015), a finding supported by epidemiologic data that 
metformin impacts Ki67 tumor expression in insulin resistant but not in insulin sensitive 
women (DeCensi et al. 2014).
In prostate cancer, although some studies report inconsistent findings (Azoulay, et al. 2011; 
Currie, et al. 2009; Franciosi, et al. 2013; Murtola, et al. 2008; Wright and Stanford 2009), 
mounting evidence supports an inverse association between metformin use and prostate 
cancer risk in men with diabetes (Clyne 2014; Preston, et al. 2014; Yu, et al. 2014a). Fewer 
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studies have examined the association between metformin use and prostate cancer 
recurrence and mortality, with somewhat mixed results. While several individual studies 
reported null findings (Allott et al. 2013a; Kaushik, et al. 2013; Patel, et al. 2010), a meta-
analysis demonstrated that metformin use was associated with reduced risk of recurrence 
following primary therapy (Yu et al. 2014a), and there is evidence to support an inverse 
association between metformin use and prostate cancer-specific mortality (Bensimon, et al. 
2014; Margel, et al. 2013), although this has not been reported by all studies (Lega, et al. 
2014). Further supporting a chemopreventive role for metformin in prostate cancer, 
metformin slowed tumor growth in a xenograft mouse model of prostate cancer (Ben Sahra, 
et al. 2008), in addition to reducing IGF1 levels and modestly counteracting the tumor-
promoting properties of a high fat diet in a small study using the TRAMP model (Xu, et al. 
2014). Finally, metformin reduced mouse prostatic intraepithelial neoplasia (mPIN) 
development and slowed transition to adenocarcinoma in the Hi-Myc transgenic mouse 
model of prostate cancer, via down regulation of Myc gene expression (Akinyeke, et al. 
2013).
While data from both preclinical and population-based studies support an antineoplastic role 
for metformin, translating findings from laboratory studies to humans is rendered more 
challenging by high metformin doses commonly used in animal and cell-based models, often 
exceeding recommended therapeutic doses in humans (Ben Sahra, et al. 2010). In addition, 
the progressive nature of diabetes and the various medications used to control it makes 
population-based research into the impact of metformin on cancer risk and mortality 
somewhat challenging. Time-related biases are a consideration in observational studies of 
drug use and may lead to overestimation of the inverse association between metformin and 
cancer (Suissa and Azoulay 2012). However, a meta-analysis of prospective studies which 
controlled for obesity status and which were not subject to time-related biases concluded 
that metformin was associated with a modest reduction in overall cancer risk (Gandini, et al. 
2014). Whether metformin should be considered as a chemopreventive agent for individuals 
without diabetes is another issue. Preclinical studies have demonstrated direct action of 
metformin on cancer cells through AMPK activation and mTOR signaling (Hardie and 
Alessi 2013; Zhou, et al. 2001), suggesting that metformin may also have chemopreventive 
properties in individuals without insulin resistance or diabetes. However, a body of evidence 
in both population and preclinical mouse models suggests that metformin impacts tumor 
growth only in the context of insulin resistance, obesity, and/or diabetes, indicating that 
improving insulin sensitivity may be a key indirect mechanism by which metformin impacts 
cancer growth (Bonanni at al. 2012; DeCensi et al. 2014; Thompson et al. 2015). This 
proposed mechanism is further supported by evidence linking elevated levels of C-peptide (a 
surrogate for insulin levels) with breast and prostate cancer-specific mortality (Goodwin, et 
al. 2012; Ma, et al. 2008). Therefore, while evidence suggests that metformin may be most 
beneficial for preventing cancer growth in insulin resistant individuals via indirect 
mechanisms, future studies should explore potential direct mechanisms using preclinical 
models and metformin doses which reflect those used in humans.
b. Inflammation and non-steroidal anti-inflammatory drugs—Chronic, low-grade 
inflammation is a hallmark of obesity, and has been proposed as a mechanistic link between 
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obesity and cancer (Colotta, et al. 2009). Metabolism of arachidonic acid, a major 
component of animal fat, by cyclooxygenase (COX) generates prostaglandin and other 
eicosanoids, a group of biologically active lipids that play a key role in inflammation. 
Obesity is associated with elevated levels of COX-2 expression and heightened 
prostaglandin signaling (Subbaramaiah, et al. 2012), suggesting a targetable inflammatory 
mechanism linking obesity and cancer. The anti-inflammatory properties of non-steroidal 
anti-inflammatory drugs (NSAIDs) are mediated via COX inhibition which, in turn, reduces 
prostaglandin levels (Wang and Dubois 2010). While the strongest evidence for a role for 
NSAIDs in chemoprevention comes from inverse associations with adenoma and colorectal 
cancer (Baron, et al. 2003; Rostom, et al. 2007), there is also support for a role for NSAIDs 
in other cancer types (Wang and Dubois 2010).
While normal breast tissue expresses low levels of COX-2, approximately 40% of invasive 
breast cancers overexpress this enzyme, and elevated levels are associated with increased 
risk of breast cancer-specific mortality (Ristimaki, et al. 2002). The inverse association 
between NSAID use and breast cancer incidence does not appear to differ significantly by 
drug type, with similar effect estimates reported for both aspirin and non-aspirin NSAIDs 
(de Pedro, et al. 2015). However, a randomized trial of low-dose aspirin failed to 
demonstrate an inverse association for breast cancer incidence (Cook, et al. 2005), 
potentially suggesting that a higher dose may be required for chemoprevention. Some 
studies report that the protective association between NSAID use and breast cancer is 
limited to hormone receptor-positive disease (de Pedro et al. 2015; Terry, et al. 2004), and 
others have reported a stronger inverse association between NSAID use and breast cancer-
specific mortality in hormone receptor-positive cases (Allott, et al. 2014d). Given that 
COX-2-mediated prostaglandin production promotes estrogen biosynthesis via up regulation 
of the aromatase pathway (Zhao, et al. 1996), there is biologic rationale to support a role for 
NSAIDs in suppressing hormone receptor-positive breast cancer incidence and progression. 
Indeed, NSAID use is associated with reduced serum estradiol levels in women with breast 
cancer (Hudson, et al. 2008), which may impact the growth of estrogen-responsive tumors. 
Finally, in further support of a true biologic association between NSAID use and breast 
cancer, there is evidence that longer duration of NSAID use is more protective for both 
breast cancer incidence (Terry et al. 2004) and breast cancer-specific mortality (Allott et al. 
2014d).
Studies in breast cancer mouse models support a role for COX-2 in promoting tumor growth 
(Liu, et al. 2001; Lyons, et al. 2011) and for selective COX-2 inhibitors, including 
celecoxib, in inhibiting tumor growth (Chang, et al. 2004). One study showed that celecoxib 
was most protective in HER2-expressing mouse models of breast cancer, via reduction of 
prostaglandin levels (Howe, et al. 2002), indicating a potential role for COX-2 inhibition in 
preventing HER2-positive breast cancer. However, while COX-2 overexpression has been 
reported in HER2-positive breast cancers in women (Ristimaki et al. 2002; Subbaramaiah, et 
al. 2002), the impact of NSAID use in this tumor subtype has not been widely examined, 
perhaps due to the relatively low frequency of HER2-enriched breast cancers in the human 
population. Finally, a study in a rat model of breast cancer showed that NSAIDs were only 
effective in hormone-responsive tumors (Woditschka, et al. 2008), supporting epidemiologic 
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literature reporting stronger associations between NSAID use and hormone receptor-positive 
breast cancer risk and mortality.
Similar to breast cancer, there is evidence for overexpression of COX-2 in prostate cancer, 
relative to non-cancerous tissue or benign prostatic hyperplasia (Yoshimura, et al. 2000), 
and elevated expression is associated with increased prostate cancer-specific mortality 
(Khor, et al. 2007). A meta-analysis reported an inverse association between NSAID use and 
aggressive prostate cancer risk which was strongest amongst aspirin users, particularly 
longer duration aspirin users (Liu, et al. 2014). However, a randomized trial of celecoxib for 
4-6 weeks in patients with localized prostate cancer had no impact on prostaglandin levels in 
the prostate (Antonarakis, et al. 2009), potentially suggesting an exposure period of 
insufficient length to impact prostate cancer biology. Interestingly, the association between 
aspirin use and aggressive prostate cancer incidence appears to differ by geographic region, 
with a significant protective effect evident in North American, but not in European studies 
(Liu et al. 2014; Wang, et al. 2014). Given that anti-inflammatory agents such as NSAIDs 
can lower PSA levels (Chang, et al. 2010), this geographic disparity in results may be 
attributable in part to differences in screening practices. However, one North American 
study where prostate cancer screening was largely independent of PSA testing reported that 
aspirin and NSAID use was associated with reduced risk of aggressive disease (Vidal, et al. 
2014), supporting a true biologic association between NSAID use and prostate cancer. 
Finally, a number of studies in the TRAMP mouse model of prostate cancer support a role 
for COX inhibition in prostate cancer chemoprevention, reporting that celecoxib reduced 
tumor size (Gupta, et al. 2004), caused regression of mPIN lesions (Narayanan, et al. 2004) 
and inhibited the development of adenocarcinoma in a dose-dependent fashion (Narayanan, 
et al. 2006).
One limitation of many observational studies of NSAID use is incomplete capture of NSAID 
use information, with many studies focusing solely on aspirin or ibuprofen use, or on 
prescription NSAIDs only (Allott et al. 2014d; de Pedro et al. 2015). Incomplete NSAID use 
data may attenuate the association between NSAID use and cancer, since “unexposed” 
individuals may have taken other types of NSAIDs that were not ascertained during data 
collection, especially given the widespread use of these drugs. In addition, confounding by 
indication is an important consideration in observational studies of NSAID use, as users may 
be more likely to have chronic conditions such as arthritis for which they are taking NSAIDs 
(Allott et al. 2014d). Finally, although epidemiologic and preclinical evidence supports a 
role for COX inhibition in chemoprevention, the clinical utility of selective COX-2 
inhibitors is limited due to cardiovascular and gastrointestinal side effects (Wang and 
Dubois 2010). As such, understanding the mechanisms linking NSAID use and cancer will 
result in the identification of additional biomarkers and therapeutic targets, potentially 
enabling the development of therapeutic agents with fewer side effects than existing COX 
inhibitors.
c. Hypercholesterolemia and statins—Hypercholesterolemia, an obesity-associated 
co-morbidity, affects approximately 20% of the US adult population (Fryar, et al. 2012). 
Cholesterol is an essential plasma membrane component of animal cells and plays a crucial 
role in maintaining membrane fluidity, in addition to regulating intracellular signaling 
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processes (Krycer and Brown 2013). The role of cholesterol as the precursor for endogenous 
sex steroid biosynthesis suggests its potential importance in both breast and prostate cancer, 
two hormone-dependent tumor types.
Dietary cholesterol intake is associated with increased risk of breast cancer, with evidence 
for a dose-dependent effect across increasing quartiles of cholesterol intake (Hu, et al. 
2012). Moreover, a large prospective study of over one million adults in Korea showed that 
serum cholesterol levels were associated with increased risk of breast cancer (Kitahara, et al. 
2011). Consistent with the role of cholesterol as a precursor for sex steroid biosynthesis, 
studies which stratified by hormone receptor status reported that elevated serum cholesterol 
levels were associated with increased risk of hormone receptor-positive disease (Fagherazzi, 
et al. 2010) and that high dietary cholesterol intake was associated with increased risk of 
ER-positive, but not ER-negative disease (Jakovljevic, et al. 2002). Finally, a recent study 
demonstrated that 27-hydroxycholesterol (27-HC), the most abundant cholesterol metabolite 
in the circulation and an endogenous selective estrogen receptor modulator (SERM), 
promoted ER-positive breast cancer progression in multiple mouse models (Nelson, et al. 
2013), suggesting a mechanistic link between cholesterol and breast cancer.
Relative to other organs of the body, normal prostate epithelial cells have high cholesterol 
content and these levels increase further during progression to prostate cancer (Krycer and 
Brown 2013), suggesting that cholesterol accumulation may be advantageous to prostate 
cancer progression. In support of this hypothesis, hypermethylation of the cholesterol efflux 
transporter ABCA1, an epigenetic silencing mechanism leading to accumulation of 
intratumoral cholesterol, has been associated with increased risk of aggressive prostate 
cancer (Lee, et al. 2013). There is a suggestion that elevated cholesterol may be associated 
with increased risk of aggressive prostate cancer (Farwell, et al. 2011; Mondul, et al. 2011; 
Platz, et al. 2008; Platz, et al. 2009; Shafique, et al. 2012) but not total prostate cancer 
(Mondul, et al. 2010; Platz et al. 2008), although other studies have reported no association 
between cholesterol or its sub-fractions and prostate cancer risk (Jacobs, et al. 2012; Martin, 
et al. 2009). While studies examining prostate cancer progression are few, positive 
associations between elevated serum cholesterol levels and risk of prostate cancer recurrence 
(Allott, et al. 2014b) and mortality (Batty, et al. 2011) have been reported. In support of 
these epidemiologic associations, cholesterol has been shown to promote prostate cancer cell 
line growth in vitro and in vivo (Zhuang, et al. 2002), while reduction of serum cholesterol 
levels lowered intratumoral androgen levels and slowed tumor growth in xenograft mouse 
models of human prostate cancer (Mostaghel, et al. 2012), supporting the hypothesis that 
steroid biosynthesis may be an important mechanism linking cholesterol and prostate cancer.
Statins are cost-effective and widely prescribed cholesterol-lowering drugs with proven 
benefits for cardiovascular disease prevention (Ridker and Cook 2013), and are used by 
approximately one in every four adults in the US population (Gu Q 2014). Statin use has 
been associated with reduced total cancer risk (Farwell, et al. 2008) and lower cancer-
specific mortality (Nielsen, et al. 2012) via a number of potential mechanisms including 
mevalonate pathway inhibition (Pelton, et al. 2012), reduced inflammation and angiogenesis 
(Pelton et al. 2012) and lower serum cholesterol levels (Demierre, et al. 2005). Given that 
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the bioavailability of statins in the circulation is low (Roy, et al. 2011), their cholesterol-
lowering properties may be the most relevant for breast and prostate cancers.
Despite biologic rationale for a role of statins in breast cancer chemoprevention, the 
majority of evidence supports no association between statin use and total breast cancer risk 
(Bonovas, et al. 2005; Undela, et al. 2012), and studies examining this association by breast 
cancer subtype are few. While one study reported reduced rates of ER-negative breast 
cancers among statin users (Kumar, et al. 2008), another found a null association overall and 
no evidence of effect modification by hormone receptor status (Desai, et al. 2013). However, 
epidemiologic evidence supports an inverse association between statin use and risk of breast 
cancer recurrence and mortality. Statin use after a breast cancer diagnosis has been 
associated with reduced risk of recurrence, with a stronger association for lipophilic statins 
(Ahern, et al. 2011; Kwan, et al. 2008). Furthermore, a study of over 30,000 breast cancer 
cases in the Finnish Cancer Registry showed an inverse effect of both pre and post-diagnosis 
statin use on breast cancer-specific mortality, with evidence for a dose and time-dependent 
effect among pre-diagnosis users (Murtola, et al. 2014). Another study in the UK Cancer 
Registry also reported a weak protective effect of statin use on breast cancer-specific 
mortality, with some evidence that simvastatin use showed the strongest association 
(Cardwell, et al. 2015). Studies stratifying by hormone receptor status are required, as this 
information has been lacking in previous studies (Cardwell et al. 2015; Murtola et al. 2014).
In prostate cancer, while the preponderance of evidence does not support an association 
between statin use and total prostate cancer risk (Bansal, et al. 2012; Bonovas, et al. 2008; 
Browning and Martin 2007; Dale, et al. 2006; Kuoppala, et al. 2008), an inverse association 
between statin use and risk of aggressive disease has been consistently reported (Bansal et 
al. 2012; Bonovas et al. 2008). Regarding prostate cancer outcomes after treatment, three 
meta-analyses have reported a null association between statin use and risk of recurrence 
(Mass, et al. 2012; Park, et al. 2013; Scosyrev, et al. 2013). However, the studies 
contributing to these meta-analyses were few and most examined statin use at the time of 
prostate cancer treatment. Given the widespread use of statins, it is likely that many 
nonusers became statin users after treatment, which may bias the results of these previous 
studies towards the null. A retrospective analysis which minimized misclassification of 
statin users by excluding prevalent users at the time of prostate cancer treatment and 
capturing statin use throughout the follow up period showed that post-diagnosis statin use 
was associated with reduced risk of recurrence (Allott, et al. 2014a), suggesting a true 
protective association between statin use and prostate cancer. Finally, an analysis of almost 
12,000 men with localized prostate cancer showed that post-diagnostic statin use was 
associated with reduced prostate cancer-specific mortality, with evidence for a stronger 
protective effect amongst those who had also used statins before diagnosis (Yu, et al. 
2014b). Given that cardiovascular disease and cancer are the two most common causes of 
mortality in the US (American Society of Clinical 2014), understanding the potential role of 
cholesterol reduction for cancer prevention will have important public health impact.
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5. Transdisciplinary challenges facing obesity and cancer research
Obesity is a complex and heterogeneous exposure, giving rise to a number of considerations 
and challenges for obesity and cancer research, particularly in translating findings from 
preclinical to population-based research, and vice versa.
First, inter-individual variation in adipose tissue distribution leads to challenges in defining 
obesity status for population-based research. BMI is a well-validated surrogate of overall 
obesity with the important strength of being widely used, thus enabling inter-study 
comparisons (Allott et al. 2013b). However, visceral obesity, accumulation of adipose tissue 
within the abdominal cavity, is a risk factor for cardiovascular disease (Neeland, et al. 2013) 
and certain types of cancer, including breast and prostate (Doyle, et al. 2012; Pischon, et al. 
2008). Population-based studies rely on waist circumference and waist-to-hip ratio as 
surrogates of visceral obesity, given that computed tomography (CT), the gold standard 
method for direct quantification of visceral fat area (VFA), is not feasible for population-
based research. While these surrogate measures correlate more strongly with VFA than BMI 
does (Allott, et al. 2014c), it is important to consider that they do not distinguish between 
subcutaneous and visceral adipose tissue at waist level (Figure 4), potentially giving rise to 
some misclassification of visceral obesity status. Despite this limitation, waist circumference 
and waist-to-hip ratio offer advantages over BMI for estimating visceral obesity, given that 
these measures are less influenced by lean body mass. Of note, the prevalence of visceral 
obesity (measured by VFA or waist circumference) in the US population is higher than that 
of overall obesity (measured by BMI), with approximately 45% of men and women 
classified as viscerally obese by VFA (Pou, et al. 2009), and approximately 40% of men and 
60% of women classified as viscerally obese by waist circumference (Li, et al. 2007), while 
only one third of individuals are classified as obese by BMI (Ogden, et al. 2014). As such, 
defining obesity using BMI underestimates the prevalence of visceral obesity in the 
population. Moreover, roughly 20% of men and 10% of women with BMI ≥30 kg/m2 do not 
have elevated VFA, while approximately 10% of men and women with BMI <30 kg/m2 
have elevated VFA (Pou et al. 2009). Misclassification of visceral obesity status 
contaminates the “unexposed” (i.e. non-obese) group with “exposed” individuals (i.e. 
viscerally obese) and vice versa, with the likely result of biasing associations between 
obesity and cancer towards the null (Figure 5).
Second, adipose tissue is a unique organ in its ability to expand and contract throughout the 
life course of the individual, and the relevant timing or “window of susceptibility” for 
obesity to impact tumor growth is unknown. Furthermore, population-based studies that 
examine weight change over the life course are usually limited to self-reported obesity 
status, and often require individuals to recollect their body weight many decades in the past. 
However, while self-reported weight is known to be systematically underreported, it remains 
predictive of obesity-associated co-morbidities and is not outperformed by corrected 
measures, indicating that it may be sufficient for population-based obesity and cancer 
research (Dutton and McLaren 2014). Another consideration is that population-based studies 
of weight change across the life course are limited both by relatively rare occurrences of 
weight loss and by unknown reasons for weight loss. As such, preclinical models provide an 
opportunity to evaluate the impact of diet-induced obesity and weight loss at different 
Allott and Hursting Page 16













“windows of susceptibility” over the life course of the mouse, for example, post pregnancy 
(Sundaram, et al. 2014a). Careful design of preclinical studies with a consideration for 
timing of weight change in relation to tumor development will help to inform research 
questions in the population-based setting.
Finally, obesity is a heterogeneous phenotype, and it may be useful to consider it a disease 
comprised of distinct subtypes (Field, et al. 2013). For example, individuals with elevated 
BMI may be further stratified according to visceral obesity, diabetes or metabolic syndrome 
status. This research approach may help us to determine, for example, whether high 
cholesterol or insulin resistance rather than obesity per se are the driving forces behind the 
obesity-cancer link. Large, population-based studies with sufficient power for stratified 
analysis by various components of obesity are required for this approach. In addition, while 
pharmacoepidemiologic studies provide insight into potential chemopreventive properties of 
a number of medications which are widely used in the treatment of obesity-associated co-
morbidities, these studies are subject to confounding by indication, in addition to other 
biases inherent in retrospective, observational studies of drug use. As such, results from 
population-based studies should be interpreted alongside preclinical findings, and alongside 
randomized controlled clinical trials.
6. Conclusions
The obesity-cancer link is of public health interest given the pervasiveness of both 
conditions, and the potentially modifiable nature of obesity. Although calorie restriction and 
weight loss are some of the most effective approaches for inhibiting tumor growth in animal 
models, weight loss is challenging for humans to achieve and maintain. Furthermore, 
observational data supporting a role for weight loss in cancer incidence and mortality in 
humans are lacking, and neither have clinical trials been conducted. While some 
epidemiologic and preclinical data suggest a chemopreventive role for agents targeting 
obesity-associated comorbidities, including metformin, NSAIDs and statins, not all studies 
support these findings and further research is needed. Given that preclinical models may be 
limited by their relevance to human cancers and observational studies are limited by non-
randomized design, integrating findings from different disciplines using a transdisciplinary 
approach may help us to gain insight into mechanisms linking obesity and cancer. An 
improved understanding of the mechanisms contributing to the obesity - cancer link will be 
important for cancer prevention and treatment efforts. In addition, given that the top five 
causes of mortality in the US are heart disease, stroke, diabetes, kidney disease and cancer 
(Schmitz et al. 2013), targeting obesity is relevant not only to improve cancer-specific 
outcomes but also to impact all-cause mortality among cancer survivors.
Acknowledgments
Funding: This work was supported by the National Cancer Institute (R35 CA197627; SDH), the Breast Cancer 
Research Foundation (SDH), and the University Cancer Research Fund of North Carolina (EHA)
Allott and Hursting Page 17














Adams TD, Stroup AM, Gress RE, Adams KF, Calle EE, Smith SC, Halverson RC, Simper SC, 
Hopkins PN, Hunt SC. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver 
Spring). 2009; 17:796–802. [PubMed: 19148123] 
Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sorensen HT, Lash TL. 
Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort 
study. J Natl Cancer Inst. 2011; 103:1461–1468. [PubMed: 21813413] 
Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer ED, Saxena A, Yan W, Logan SK, Li X. 
Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis. 2013; 34:2823–
2832. [PubMed: 24130167] 
Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg 
MR, Moorman PG, et al. Metformin does not affect risk of biochemical recurrence following 
radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis. 2013a; 
16:391–397. [PubMed: 24100644] 
Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland 
SJ. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: 
Results from the SEARCH database. BJU Int. 2014a; 114:661–666. [PubMed: 24588774] 
Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland 
SJ. Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH 
Database. Cancer Epidemiol Biomarkers Prev. 2014b; 23:2349–2356. [PubMed: 25304929] 
Allott EH, Howard LE, Song HJ, Sourbeer KN, Koontz BF, Salama JK, Freedland SJ. Racial 
differences in adipose tissue distribution and risk of aggressive prostate cancer among men 
undergoing radiotherapy. Cancer Epidemiol Biomarkers Prev. 2014c; 23:2404–2412. [PubMed: 
25146088] 
Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 
2013b; 63:800–809. [PubMed: 23219374] 
Allott EH, Tse CK, Olshan AF, Carey LA, Moorman PG, Troester MA. Non-steroidal anti-
inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina 
Breast Cancer Study. Breast Cancer Res Treat. 2014d; 147:415–421. [PubMed: 25151293] 
Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of 
hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol 
Biomarkers Prev. 2004; 13:1558–1568. [PubMed: 15466970] 
American Society of Clinical Oncology. The state of cancer care in America, 2014: a report by the 
American Society of Clinical Oncology. J Oncol Pract. 2014; 10:119–142. [PubMed: 24618075] 
Amy NK, Aalborg A, Lyons P, Keranen L. Barriers to routine gynecological cancer screening for 
White and African-American obese women. Int J Obes (Lond). 2006; 30:147–155. [PubMed: 
16231037] 
Andersson SO, Wolk A, Bergstrom R, Adami HO, Engholm G, Englund A, Nyren O. Body size and 
prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl 
Cancer Inst. 1997; 89:385–389. [PubMed: 9060961] 
Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, 
Anikin IV, Karkach AS, Romanyukha AA. Metformin extends life span of HER-2/neu transgenic 
mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell 
Cycle. 2010; 9:188–197. [PubMed: 20016287] 
Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, Zahurak ML, 
Piantadosi S, Dannenberg AJ, Gurganus RT, et al. Phase II, randomized, placebo-controlled trial 
of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-
specific biomarkers. J Clin Oncol. 2009; 27:4986–4993. [PubMed: 19720908] 
Arnold M, Pandeya N, Byrnes G, Renehan AG, Stevens GA, Ezzati M, Ferlay J, Miranda JJ, Romieu 
I, Dikshit R, et al. Global burden of cancer attributable to high body-mass index in 2012: a 
population-based study. Lancet Oncol. 2014; 16:36–46. [PubMed: 25467404] 
Allott and Hursting Page 18













Ashrafian H, Ahmed K, Rowland SP, Patel VM, Gooderham NJ, Holmes E, Darzi A, Athanasiou T. 
Metabolic surgery and cancer: protective effects of bariatric procedures. Cancer. 2011; 117:1788–
1799. [PubMed: 21509756] 
Azoulay L, Dell'Aniello S, Gagnon B, Pollak M, Suissa S. Metformin and the incidence of prostate 
cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev. 2011; 20:337–344. 
[PubMed: 21148757] 
Azrad M, Demark-Wahnefried W. The association between adiposity and breast cancer recurrence and 
survival: A review of the recent literature. Curr Nutr Rep. 2014; 3:9–15. [PubMed: 24533234] 
Banegas JR, Lopez-Garcia E, Gutierrez-Fisac JL, Guallar-Castillon P, Rodriguez-Artalejo F. A simple 
estimate of mortality attributable to excess weight in the European Union. Eur J Clin Nutr. 2003; 
57:201–208. [PubMed: 12571650] 
Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson 
WJ, Presti JC Jr, et al. Obesity-related plasma hemodilution and PSA concentration among men 
with prostate cancer. JAMA. 2007; 298:2275–2280. [PubMed: 18029831] 
Bansal D, Undela K, D'Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of 
observational studies. PLoS One. 2012; 7:e46691. [PubMed: 23049713] 
Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers 
RW, Rothstein R, Burke CA, et al. A randomized trial of aspirin to prevent colorectal adenomas. 
N Engl J Med. 2003; 348:891–899. [PubMed: 12621133] 
Bassett JK, Severi G, Baglietto L, Macinnis RJ, Hoang HN, Hopper JL, English DR, Giles GG. 
Weight change and prostate cancer incidence and mortality. Int J Cancer. 2011; 131:1711–1719. 
[PubMed: 22213024] 
Batty GD, Kivimaki M, Clarke R, Davey Smith G, Shipley MJ. Modifiable risk factors for prostate 
cancer mortality in London: forty years of follow-up in the Whitehall study. Cancer Causes 
Control. 2011; 22:311–318. [PubMed: 21116843] 
Befort CA, Klemp JR, Austin HL, Perri MG, Schmitz KH, Sullivan DK, Fabian CJ. Outcomes of a 
weight loss intervention among rural breast cancer survivors. Breast Cancer Res Treat. 2012; 
132:631–639. [PubMed: 22198470] 
Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le 
Marchand-Brustel Y, Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro 
and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27:3576–3586. [PubMed: 
18212742] 
Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new 
perspective for an old antidiabetic drug? Mol Cancer Ther. 2010; 9:1092–1099. [PubMed: 
20442309] 
Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L. The use of metformin in patients with prostate 
cancer and the risk of death. Cancer Epidemiol Biomarkers Prev. 2014; 23:2111–2118. [PubMed: 
25017246] 
Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in 
Europe. Int J Cancer. 2001; 91:421–430. [PubMed: 11169969] 
Berstein LM, Boyarkina MP, Tsyrlina EV, Turkevich EA, Semiglazov VF. More favorable 
progesterone receptor phenotype of breast cancer in diabetics treated with metformin. Med Oncol. 
2011; 28:1260–1263. [PubMed: 20490716] 
Besic N, Satej N, Ratosa I, Horvat AG, Marinko T, Gazic B, Petric R. Long-term use of metformin 
and the molecular subtype in invasive breast carcinoma patients - a retrospective study of clinical 
and tumor characteristics. BMC Cancer. 2014; 14:298. [PubMed: 24774412] 
Bicakli DH, Varol U, Degirmenci M, Tunali D, Cakar B, Durusoy R, Karaca B, Ali Sanli U, Uslu R. 
Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients 
with breast cancer. J Oncol Pharm Pract. 2014
Blando J, Moore T, Hursting S, Jiang G, Saha A, Beltran L, Shen J, Repass J, Strom S, DiGiovanni J. 
Dietary energy balance modulates prostate cancer progression in Hi-Myc mice. Cancer Prev Res 
(Phila). 2011; 4:2002–2014. [PubMed: 21952584] 
Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, 
Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni 
Allott and Hursting Page 19













M, Varricchio C, Viale G, Bruzzi P, Decensi A. Dual effect of metformin on breast cancer 
proliferation in a randomized presurgical trial. J Clin Oncol. 2012; 30:2593–2600. [PubMed: 
22564993] 
Bonn SE, Wiklund F, Sjolander A, Szulkin R, Stattin P, Holmberg E, Gronberg H, Balter K. Body 
mass index and weight change in men with prostate cancer: progression and mortality. Cancer 
Causes Control. 2014; 25:933–943. [PubMed: 24810654] 
Bonorden MJ, Grossmann ME, Ewing SA, Rogozina OP, Ray A, Nkhata KJ, Liao DJ, Grande JP, 
Cleary MP. Growth and Progression of TRAMP Prostate Tumors in Relationship to Diet and 
Obesity. Prostate Cancer. 2012; 201210.1155/2012/543970
Bonorden MJ, Rogozina OP, Kluczny CM, Grossmann ME, Grande JP, Lokshin A, Cleary MP. Cross-
sectional analysis of intermittent versus chronic caloric restriction in the TRAMP mouse. Prostate. 
2009; 69:317–326. [PubMed: 19016490] 
Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: A metaanalysis of 6 
randomized clinical trials and 13 observational studies. Int J Cancer. 2008; 123:899–904. 
[PubMed: 18491405] 
Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of 
seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005; 23:8606–8612. 
[PubMed: 16260694] 
Borowsky AD. Choosing a mouse model: experimental biology in context--the utility and limitations 
of mouse models of breast cancer. Cold Spring Harb Perspect Biol. 2011; 310.1101/
cshperspect.a009670
Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of 
diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes 
prevalence. Popul Health Metr. 2010; 8:29. [PubMed: 20969750] 
Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J 
Cancer. 2007; 120:833–843. [PubMed: 17131313] 
Buschemeyer WC 3rd, Klink JC, Mavropoulos JC, Poulton SH, Demark-Wahnefried W, Hursting SD, 
Cohen P, Hwang D, Johnson TL, Freedland SJ. Effect of intermittent fasting with or without 
caloric restriction on prostate cancer growth and survival in SCID mice. Prostate. 2010; 70:1037–
1043. [PubMed: 20166128] 
Cai H, Xu Z, Xu T, Yu B, Zou Q. Diabetes mellitus is associated with elevated risk of mortality 
amongst patients with prostate cancer: a meta-analysis of 11 cohort studies. Diabetes Metab Res 
Rev. 2014
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from 
cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348:1625–1638. 
[PubMed: 12711737] 
Campos-Gomez S, Valero V, Flores-Arredondo JH, Isassi-Chapa A, Rangel-Rodriguez I, Hortobagyi 
GN, Gonzalez-Angulo AM. Breast cancer subtype and baseline characteristics from diabetic breast 
cancer patients are not different from nondiabetics. Breast J. 2014; 20:434–436. [PubMed: 
24862358] 
Canchola AJ, Anton-Culver H, Bernstein L, Clarke CA, Henderson K, Ma H, Ursin G, Horn-Ross PL. 
Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study 
cohort. Cancer Causes Control. 2012; 23:473–485.
Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a 
systematic review and meta-analysis. Cancer Prev Res (Phila). 2011; 4:486–501. [PubMed: 
21233290] 
Cardwell CR, Hicks BM, Hughes C, Murray LJ. Statin use after diagnosis of breast cancer and 
survival: a population-based cohort study. Epidemiology. 2015; 26:68–78. [PubMed: 25304447] 
Carmichael AR, Bates T. Obesity and breast cancer: a review of the literature. Breast. 2004; 13:85–92. 
[PubMed: 15019686] 
Centers for Disease Control & Prevention. Cancer survivors--United States, 2007. MMWR Morb 
Mortal Wkly Rep. 2011; 60:269–272. [PubMed: 21389929] 
Allott and Hursting Page 20













Chamberlain C, Romundstad P, Vatten L, Gunnell D, Martin RM. The association of weight gain 
during adulthood with prostate cancer incidence and survival: a population-based cohort. Int J 
Cancer. 2011; 129:1199–1206. [PubMed: 21064096] 
Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, Navarro Rosenblatt D, 
Thune I, Vieira R, Norat T. Body mass index and survival in women with breast cancer-systematic 
literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014; 25:1901–1914. 
[PubMed: 24769692] 
Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF, Hla T. Role of 
prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer 
progression. Proc Natl Acad Sci U S A. 2004; 101:591–596. [PubMed: 14688410] 
Chang SL, Harshman LC, Presti JC Jr. Impact of common medications on serum total prostate-specific 
antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol. 
2010; 28:3951–3957. [PubMed: 20679596] 
Chu DI, De Nunzio C, Gerber L, Thomas JA 2nd, Calloway EE, Albisinni S, Senocak C, McKeever 
MG, Moreira DM, Tubaro A, et al. Predictive value of digital rectal examination for prostate 
cancer detection is modified by obesity. Prostate Cancer Prostatic Dis. 2011; 14:346–353. 
[PubMed: 21727906] 
Cleary MP, Grande JP, Juneja SC, Maihle NJ. Diet-induced obesity and mammary tumor development 
in MMTV-neu female mice. Nutr Cancer. 2004; 50:174–180. [PubMed: 15623464] 
Cleveland RJ, Eng SM, Abrahamson PE, Britton JA, Teitelbaum SL, Neugut AI, Gammon MD. 
Weight gain prior to diagnosis and survival from breast cancer. Cancer Epidemiol Biomarkers 
Prev. 2007; 16:1803–1811. [PubMed: 17855698] 
Clyne M. Prostate cancer: metformin--the new wonder drug? Nat Rev Urol. 2014; 11:366. [PubMed: 
24914783] 
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh 
hallmark of cancer: links to genetic instability. Carcinogenesis. 2009; 30:1073–1081. [PubMed: 
19468060] 
Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Low-
dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized 
controlled trial. JAMA. 2005; 294:47–55. [PubMed: 15998890] 
Cui Y, Whiteman MK, Flaws JA, Langenberg P, Tkaczuk KH, Bush TL. Body mass and stage of 
breast cancer at diagnosis. Int J Cancer. 2002; 98:279–283. [PubMed: 11857420] 
Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 
diabetes. Diabetologia. 2009; 52:1766–1777. [PubMed: 19572116] 
Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident 
cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes 
Care. 2012; 35:299–304. [PubMed: 22266734] 
Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. 
JAMA. 2006; 295:74–80. [PubMed: 16391219] 
De Angel RE, Conti CJ, Wheatley KE, Brenner AJ, Otto G, Degraffenried LA, Hursting SD. The 
enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation 
persist after weight loss and are reversed by RAD001. Mol Carcinog. 2013; 52:446–458. 
[PubMed: 22290600] 
de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, 
Nordenskjold B, Gutierez J, Andersson M, et al. The effect of body mass index on overall and 
disease-free survival in node-positive breast cancer patients treated with docetaxel and 
doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast 
Cancer Res Treat. 2010; 119:145–153. [PubMed: 19731015] 
De Bruijn KM, Arends LR, Hansen BE, Leeflang S, Ruiter R, van Eijck CH. Systematic review and 
meta-analysis of the association between diabetes mellitus and incidence and mortality in breast 
and colorectal cancer. Br J Surg. 2013; 100:1421–1429. [PubMed: 24037561] 
de Pedro M, Baeza S, Escudero MT, Dierssen-Sotos T, Gomez-Acebo I, Pollan M, Llorca J. Effect of 
COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-
analysis. Breast Cancer Res Treat. 2015; 149:525–536. [PubMed: 25589172] 
Allott and Hursting Page 21













DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, 
Serrano D, Schwab M, Hofmann U, et al. Differential effects of metformin on breast cancer 
proliferation according to markers of insulin resistance and tumor subtype in a randomized 
presurgical trial. Breast Cancer Res Treat. 2014; 148:81–90. [PubMed: 25253174] 
Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and 
cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 
2010; 3:1451–1461. [PubMed: 20947488] 
Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev 
Cancer. 2005; 5:930–942. [PubMed: 16341084] 
Desai P, Chlebowski R, Cauley JA, Manson JE, Wu C, Martin LW, Jay A, Bock C, Cote M, Petrucelli 
N, et al. Prospective analysis of association between statin use and breast cancer risk in the 
women's health initiative. Cancer Epidemiol Biomarkers Prev. 2013; 22:1868–1876. [PubMed: 
23975947] 
Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP. Obesity, tamoxifen use, and 
outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst. 
2003; 95:1467–1476. [PubMed: 14519753] 
Dogan S, Hu X, Zhang Y, Maihle NJ, Grande JP, Cleary MP. Effects of high-fat diet and/or body 
weight on mammary tumor leptin and apoptosis signaling pathways in MMTV-TGF-alpha mice. 
Breast Cancer Res. 2007; 9:R91. [PubMed: 18162139] 
Doyle SL, Donohoe CL, Lysaght J, Reynolds JV. Visceral obesity, metabolic syndrome, insulin 
resistance and cancer. Proc Nutr Soc. 2012; 71:181–189. [PubMed: 22051112] 
Dunlap SM, Chiao LJ, Nogueira L, Usary J, Perou CM, Varticovski L, Hursting SD. Dietary energy 
balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-
low and basal-like mammary tumor models. Cancer Prevention Research. 2012a; 5:930–942. 
[PubMed: 22588949] 
Dutton DJ, McLaren L. The usefulness of “corrected” body mass index vs. self-reported body mass 
index: comparing the population distributions, sensitivity, specificity, and predictive utility of 
three correction equations using Canadian population-based data. BMC Public Health. 2014; 
14:430. [PubMed: 24885210] 
Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of 
postmenopausal breast cancer. JAMA. 2006; 296:193–201. [PubMed: 16835425] 
Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, 
Sawyers CL. Myc-driven murine prostate cancer shares molecular features with human prostate 
tumors. Cancer Cell. 2003; 4:223–238. [PubMed: 14522256] 
Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of 
cancer in diabetic patients. BMJ. 2005; 330:1304–1305. [PubMed: 15849206] 
Fabian CJ, Kimler BF, Donnelly JE, Sullivan DK, Klemp JR, Petroff BK, Phillips TA, Metheny T, 
Aversman S, Yeh HW, et al. Favorable modulation of benign breast tissue and serum risk 
biomarkers is associated with > 10 % weight loss in postmenopausal women. Breast Cancer Res 
Treat. 2013; 142:119–132. [PubMed: 24141897] 
Fagan HB, Wender R, Myers RE, Petrelli N. Obesity and Cancer Screening according to Race and 
Gender. J Obes. 2011; 2011:218250. [PubMed: 22220270] 
Fagherazzi G, Fabre A, Boutron-Ruault MC, Clavel-Chapelon F. Serum cholesterol level, use of a 
cholesterol-lowering drug, and breast cancer: results from the prospective E3N cohort. Eur J 
Cancer Prev. 2010; 19:120–125. [PubMed: 20042864] 
Farwell WR, D'Avolio LW, Scranton RE, Lawler EV, Gaziano JM. Statins and prostate cancer 
diagnosis and grade in a veterans population. J Natl Cancer Inst. 2011; 103:885–892. [PubMed: 
21498780] 
Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, Gaziano JM. The association 
between statins and cancer incidence in a veterans population. J Natl Cancer Inst. 2008; 100:134–
139. [PubMed: 18182618] 
Field AE, Camargo CA Jr, Ogino S. The merits of subtyping obesity: one size does not fit all. JAMA. 
2013; 310:2147–2148. [PubMed: 24189835] 
Allott and Hursting Page 22













Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu 
Y, Bahalim AN, et al. National, regional, and global trends in body-mass index since 1980: 
systematic analysis of health examination surveys and epidemiological studies with 960 country-
years and 9.1 million participants. Lancet. 2011; 377:557–567. [PubMed: 21295846] 
Ford NA, Lashinger LM, Allott EH, Hursting SD. Mechanistic targets and phytochemical strategies 
for breaking the obesity-cancer link. Front Oncol. 2013a; 3:209. [PubMed: 23967401] 
Ford NA, Nunez NP, Holcomb VB, Hursting SD. IGF1 dependence of dietary energy balance effects 
on murine Met1 mammary tumor progression, epithelial-to-mesenchymal transition, and 
chemokine expression. Endocr Relat Cancer. 2013b; 20:39–51. [PubMed: 23152442] 
Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and 
risk of cancer in patients with type 2 diabetes: systematic review. PLos One. 2013; 8:e71583. 
[PubMed: 23936520] 
Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Isaacs WB, Epstein JI, Partin AW. 
Obesity and capsular incision at the time of open retropubic radical prostatectomy. J Urol. 2005; 
174:1798–1801. [PubMed: 16217290] 
Freedland SJ, Platz EA, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, Terris MK. Obesity, serum 
prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol. 2006; 
175:500–504. [PubMed: 16406980] 
Freedland SJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Trock B, Aronson WJ. Obesity and 
biochemical outcome following radical prostatectomy for organ confined disease with negative 
surgical margins. J Urol. 2004; 172:520–524. [PubMed: 15247719] 
Friedman AM, Hemler JR, Rossetti E, Clemow LP, Ferrante JM. Obese women's barriers to 
mammography and pap smear: the possible role of personality. Obesity (Silver Spring). 2012; 
20:1611–1617. [PubMed: 22370590] 
Fryar, CD.; Chen, TC.; Li, X. NCHS Data Brief. 2012. Prevalence of uncontrolled risk factors for 
cardiovascular disease: United States, 1999-2010; p. 1-8.
Fuentes-Mattei E, Velazquez-Torres G, Phan L, Zhang F, Chou PC, Shin JH, Choi HH, Chen JS, Zhao 
R, Chen J, et al. Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen 
receptor-positive breast cancer. J Natl Cancer Inst. 2014; 106
Galet C, Gray A, Said JW, Castor B, Wan J, Beltran PJ, Calzone FJ, Elashoff D, Cohen P, Aronson 
WJ. Effects of Calorie Restriction and IGF-1 Receptor Blockade on the Progression of 22Rv1 
Prostate Cancer Xenografts. Int J Mol Sci. 2013; 14:13782–13795. [PubMed: 23823800] 
Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, Szabo E. Metformin 
and cancer risk and mortality: a systematic review and meta-analysis taking into account biases 
and confounders. Cancer Prev Res (Phila). 2014; 7:867–885. [PubMed: 24985407] 
Gaudet MM, Press MF, Haile RW, Lynch CF, Glaser SL, Schildkraut J, Gammon MD, Douglas 
Thompson W, Bernstein JL. Risk factors by molecular subtypes of breast cancer across a 
population-based study of women 56 years or younger. Breast Cancer Res Treat. 2011; 130:587–
597. [PubMed: 21667121] 
Giles ED, Wellberg EA, Astling DP, Anderson SM, Thor AD, Jindal S, Tan AC, Schedin PS, Maclean 
PS. Obesity and overfeeding affecting both tumor and systemic metabolism activates the 
progesterone receptor to contribute to postmenopausal breast cancer. Cancer Res. 2012; 
72:6490–6501. [PubMed: 23222299] 
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, 
Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 2010; 33:1674–
1685. [PubMed: 20587728] 
Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Taylor SK, Hood N. Insulin- and obesity-
related variables in early-stage breast cancer: correlations and time course of prognostic 
associations. J Clin Oncol. 2012; 30:164–171. [PubMed: 22162568] 
Goodwin PJ, Pritchard KI. Obesity and hormone therapy in breast cancer: an unfinished puzzle. J Clin 
Oncol. 2010; 28:3405–3407. [PubMed: 20548001] 
Goodwin PJ, Segal RJ, Vallis M, Ligibel JA, Pond GR, Robidoux A, Blackburn GL, Findlay B, 
Gralow JR, Mukherjee S, et al. Randomized trial of a telephone-based weight loss intervention in 
Allott and Hursting Page 23













postmenopausal women with breast cancer receiving letrozole: the LISA trial. J Clin Oncol. 
2014; 32:2231–2239. [PubMed: 24934783] 
Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, 
Runowicz CD, Rosner GL, et al. Appropriate chemotherapy dosing for obese adult patients with 
cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012; 
30:1553–1561. [PubMed: 22473167] 
Grubb RL 3rd, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE, Riley TL, Ragard LR, Prorok 
PC, Berg CD, et al. Serum prostate-specific antigen hemodilution among obese men undergoing 
screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer 
Epidemiol Biomarkers Prev. 2009; 18:748–751. [PubMed: 19258472] 
Gu, Q.; P, RR.; Burt, VL.; Kit, BK. NCHS data brief. 2014. Prescription cholesterol-lowering 
medication use in adults aged 40 and over: United States, 2003-2012; p. 1-8.
Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P, Mukhtar H. 
Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic 
adenocarcinoma of the mouse prostate model. Cancer Res. 2004; 64:3334–3343. [PubMed: 
15126378] 
Hakkak R, MacLeod S, Shaaf S, Holley AW, Simpson P, Fuchs G, Jo CH, Kieber-Emmons T, 
Korourian S. Obesity increases the incidence of 7,12-dimethylbenz(a)anthracene-induced 
mammary tumors in an ovariectomized Zucker rat model. Int J Oncol. 2007; 30:557–563. 
[PubMed: 17273756] 
Hardie DG, Alessi DR. LKB1 and AMPK and the cancer-metabolism link – ten years after. BMC Biol. 
2013; 11:36. [PubMed: 23587167] 
Harvie M, Howell A, Vierkant RA, Kumar N, Cerhan JR, Kelemen LE, Folsom AR, Sellers TA. 
Association of gain and loss of weight before and after menopause with risk of postmenopausal 
breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev. 2005; 
14:656–661. [PubMed: 15767346] 
Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G, Cuzick J, Jebb SA, Martin B, 
Cutler RG, et al. The effects of intermittent or continuous energy restriction on weight loss and 
metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes 
(Lond). 2011; 35:714–727. [PubMed: 20921964] 
He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are 
associated with improved breast cancer-specific survival of diabetic women with HER2+ breast 
cancer. Ann Oncol. 2012; 23:1771–1780. [PubMed: 22112968] 
Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, 
Assefnia S, Chandrasekharan S, et al. Identification of conserved gene expression features 
between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007; 
8:R76. [PubMed: 17493263] 
Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, 
Brown AM, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human 
epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res. 2002; 
62:5405–5407. [PubMed: 12359744] 
Hu J, La Vecchia C, de Groh M, Negri E, Morrison H, Mery L. Canadian Cancer Registries 
Epidemiology Research Group. Dietary cholesterol intake and cancer. Ann Oncol. 2012; 23:491–
500. [PubMed: 21543628] 
Hu MB, Liu SH, Jiang HW, Bai PD, Ding Q. Obesity affects the biopsy-mediated detection of prostate 
cancer, particularly high-grade prostate cancer: a dose-response meta-analysis of 29,464 patients. 
PLoS One. 2014; 9:e106677. [PubMed: 25184215] 
Hudson AG, Gierach GL, Modugno F, Simpson J, Wilson JW, Evans RW, Vogel VG, Weissfeld JL. 
Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women. 
Cancer Epidemiol Biomarkers Prev. 2008; 17:680–687. [PubMed: 18349287] 
Hursting SD, Smith SM, Lashinger LM, Harvey AE, Perkins SN. Calories and carcinogenesis: lessons 
learned from 30 years of calorie restriction research. Carcinogenesis. 2010; 31:83–89. [PubMed: 
19969554] 
Allott and Hursting Page 24













Ioannides SJ, Barlow PL, Elwood JM, Porter D. Effect of obesity on aromatase inhibitor efficacy in 
postmenopausal, hormone receptor-positive breast cancer: a systematic review. Breast Cancer 
Res Treat. 2014; 147:237–248. [PubMed: 25119728] 
Irwin ML. Weight loss interventions and breast cancer survival: the time is now. J Clin Oncol. 2014; 
32:2197–2199. [PubMed: 24934785] 
Jacobs EJ, Stevens VL, Newton CC, Gapstur SM. Plasma total, LDL, and HDL cholesterol and risk of 
aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes 
Control. 2012; 23:1289–1296. [PubMed: 22692409] 
Jakovljevic J, Touillaud MS, Bondy ML, Singletary SE, Pillow PC, Chang S. Dietary intake of 
selected fatty acids, cholesterol and carotenoids and estrogen receptor status in premenopausal 
breast cancer patients. Breast Cancer Res Treat. 2002; 75:5–14. [PubMed: 12500930] 
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 
2011; 61:69–90. [PubMed: 21296855] 
Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH. Obesity, diabetes, and 
survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol. 2013; 
24:2506–2514. [PubMed: 23793035] 
Joshu CE, Mondul AM, Menke A, Meinhold C, Han M, Humphreys EB, Freedland SJ, Walsh PC, 
Platz EA. Weight gain is associated with an increased risk of prostate cancer recurrence after 
prostatectomy in the PSA era. Cancer Prev Res (Phila). 2011; 4:544–551. [PubMed: 21325564] 
Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer 
Epidemiol Biomarkers Prev. 2006; 15:2056–2062. [PubMed: 17119028] 
Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health 
professionals follow-up study. Int J Cancer. 2009; 124:1398–1403. [PubMed: 19058180] 
Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE, Bergstralh EJ. Effect of metformin on 
prostate cancer outcomes after radical prostatectomy. Urol Oncol. 2013; 32:43e1–7. [PubMed: 
23810664] 
Kerlikowske K, Walker R, Miglioretti DL, Desai A, Ballard-Barbash R, Buist DS. Obesity, 
mammography use and accuracy, and advanced breast cancer risk. J Natl Cancer Inst. 2008; 
100:1724–1733. [PubMed: 19033562] 
Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ. Obesity is associated 
with castration-resistant disease and metastasis in men treated with androgen deprivation therapy 
after radical prostatectomy: results from the SEARCH database. BJU Int. 2011; 110:492–498. 
[PubMed: 22094083] 
Khor LY, Bae K, Pollack A, Hammond ME, Grignon DJ, Venkatesan VM, Rosenthal SA, Ritter MA, 
Sandler HM, Hanks GE, et al. COX-2 expression predicts prostate-cancer outcome: analysis of 
data from the RTOG 92-02 trial. Lancet Oncol. 2007; 8:912–920. [PubMed: 17881290] 
Kitahara CM, Berrington de Gonzalez A, Freedman ND, Huxley R, Mok Y, Jee SH, Samet JM. Total 
cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011; 29:1592–
1598. [PubMed: 21422422] 
Kobayashi N, Barnard RJ, Said J, Hong-Gonzalez J, Corman DM, Ku M, Doan NB, Gui D, Elashoff 
D, Cohen P, et al. Effect of low-fat diet on development of prostate cancer and Akt 
phosphorylation in the Hi-Myc transgenic mouse model. Cancer Res. 2008; 68:3066–3073. 
[PubMed: 18413778] 
Kowall B, Stang A, Rathmann W, Kostev K. No reduced risk of overall, colorectal, lung, breast, and 
prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and 
the UK. Pharmacoepidemiol Drug Saf. 2015; 24:865–874. [PubMed: 26132313] 
Krycer JR, Brown AJ. Cholesterol accumulation in prostate cancer: a classic observation from a 
modern perspective. Biochim Biophys Acta. 2013; 1835:219–229. [PubMed: 23357067] 
Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman LJ. Estrogen receptor-negative 
breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers 
Prev. 2008; 17:1028–1033. [PubMed: 18463402] 
Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. Eur 
J Cancer. 2008; 44:2122–2132. [PubMed: 18707867] 
Allott and Hursting Page 25













Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B. Post-diagnosis statin use and breast cancer 
recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res 
Treat. 2008; 109:573–579. [PubMed: 17674197] 
Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J 
Cancer. 2007; 121:856–862. [PubMed: 17397032] 
Lashinger LM, Ford NA, Hursting SD. Interacting inflammatory and growth factor signals underlie the 
obesity-cancer link. J Nutr. 2014a; 144:109–113. [PubMed: 24285690] 
Lashinger LM, Rossi EL, Hursting SD. Obesity and resistance to cancer chemotherapy: interacting 
roles of inflammation and metabolic dysregulation. Clin Pharmacol Ther. 2014b; 96:458–463. 
[PubMed: 24960521] 
Lee BH, Taylor MG, Robinet P, Smith JD, Schweitzer J, Sehayek E, Falzarano SM, Magi-Galluzzi C, 
Klein EA, Ting AH. Dysregulation of cholesterol homeostasis in human prostate cancer through 
loss of ABCA1. Cancer Res. 2013; 73:1211–1218. [PubMed: 23233737] 
Lega IC, Shah PS, Margel D, Beyene J, Rochon PA, Lipscombe LL. The effect of metformin on 
mortality following cancer among patients with diabetes. Cancer Epidemiol Biomarkers Prev. 
2014; 23:1974–1984. [PubMed: 25030683] 
Li C, Ford ES, McGuire LC, Mokdad AH. Increasing trends in waist circumference and abdominal 
obesity among US adults. Obesity (Silver Spring). 2007; 15:216–224. [PubMed: 17228050] 
Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, Mahabir S, 
Hortobagyi GN, Brewster AM. Relationship between obesity and pathologic response to 
neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol. 2008; 
26:4072–4077. [PubMed: 18757321] 
Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T. 
Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J 
Biol Chem. 2001; 276:18563–18569. [PubMed: 11278747] 
Liu J, Ramakrishnan SK, Khuder SS, Kaw MK, Muturi HT, Lester SG, Lee SJ, Fedorova LV, Kim AJ, 
Mohamed IE, et al. High-calorie diet exacerbates prostate neoplasia in mice with 
haploinsufficiency of Pten tumor suppressor gene. Mol Metab. 2015; 4:186–198. [PubMed: 
25737954] 
Liu Y, Chen JQ, Xie L, Wang J, Li T, He Y, Gao Y, Qin X, Li S. Effect of aspirin and other non-
steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review 
and meta-analysis. BMC Med. 2014; 12:55. [PubMed: 24678716] 
Llaverias G, Danilo C, Wang Y, Witkiewicz AK, Daumer K, Lisanti MP, Frank PG. A Western-type 
diet accelerates tumor progression in an autochthonous mouse model of prostate cancer. Am J 
Pathol. 2010; 177:3180–3191. [PubMed: 21088217] 
Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast 
cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003; 21:4524–
4531. [PubMed: 14673039] 
Lyman GH, Sparreboom A. Chemotherapy dosing in overweight and obese patients with cancer. Nat 
Rev Clin Oncol. 2013; 10:451–459. [PubMed: 23856744] 
Lyons TR, O'Brien J, Borges VF, Conklin MW, Keely PJ, Eliceiri KW, Marusyk A, Tan AC, Schedin 
P. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through 
collagen and COX-2. Nat Med. 2011; 17:1109–1115. [PubMed: 21822285] 
Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ. 
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific 
mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008; 
9:1039–1047. [PubMed: 18835745] 
MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and 
meta-regression analysis. Cancer Causes Control. 2006; 17:989–1003. [PubMed: 16933050] 
Makari-Judson G, Braun B, Jerry DJ, Mertens WC. Weight gain following breast cancer diagnosis: 
Implication and proposed mechanisms. World J Clin Oncol. 2014; 5:272–282. [PubMed: 
25114844] 
Allott and Hursting Page 26













Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N. Metformin use 
and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol. 
2013; 31:3069–3075. [PubMed: 23918942] 
Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI. Components of the metabolic syndrome 
and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control. 2009; 
20:1181–1192. [PubMed: 19277881] 
Maruthur NM, Bolen S, Brancati FL, Clark JM. Obesity and mammography: a systematic review and 
meta-analysis. J Gen Intern Med. 2009; 24:665–677. [PubMed: 19277790] 
Mass AY, Agalliu I, Laze J, Lepor H. Preoperative statin therapy is not associated with biochemical 
recurrence after radical prostatectomy: our experience and meta-analysis. J Urol. 2012; 188:786–
791. [PubMed: 22818136] 
Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Adamovich E. Obesity is not 
predictive of overall survival following permanent prostate brachytherapy. Am J Clin Oncol. 
2007; 30:588–596. [PubMed: 18091052] 
Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA, Manson JE. Nurses' 
Health S. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. 
Diabetes Care. 2003; 26:1752–1758. [PubMed: 12766105] 
Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, 
Geradts J, Bensen JT, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 
2008; 109:123–139. [PubMed: 17578664] 
Mizuno NK, Rogozina OP, Seppanen CM, Liao DJ, Cleary MP, Grossmann ME. Combination of 
intermittent calorie restriction and eicosapentaenoic acid for inhibition of mammary tumors. 
Cancer Prevention Research. 2013; 6:540–547. [PubMed: 23550153] 
Moller E, Adami HO, Mucci LA, Lundholm C, Bellocco R, Johansson JE, Gronberg H, Balter K. 
Lifetime body size and prostate cancer risk in a population-based case-control study in Sweden. 
Cancer Causes Control. 2013; 24:2143–2155. [PubMed: 24048969] 
Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol 
concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control. 2010; 
21:61–68. [PubMed: 19806465] 
Mondul AM, Weinstein SJ, Virtamo J, Albanes D. Serum total and HDL cholesterol and risk of 
prostate cancer. Cancer Causes Control. 2011; 22:1545–1552. [PubMed: 21915616] 
Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford 
JL, Stroup AM, Resnick MJ, et al. Influence of Age on Incident Diabetes and Cardiovascular 
Disease Among Prostate Cancer Survivors Receiving Androgen Deprivation Therapy. J Urol. 
2014; 193:1226–1231. [PubMed: 25451829] 
Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB. Impact of circulating 
cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS 
One. 2012; 7:e30062. [PubMed: 22279565] 
Moyer VA. U.S. Preventative Services Task Force. Screening for prostate cancer: U.S. Preventive 
Services Task Force recommendation statement. Ann Intern Med. 2012; 157:120–134. [PubMed: 
22801674] 
Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast 
cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. 
Epidemiol Rev. 2014; 36:114–136. [PubMed: 24375928] 
Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Antidiabetic medication and prostate cancer risk: a 
population-based case-control study. Am J Epidemiol. 2008; 168:925–931. [PubMed: 18700234] 
Murtola TJ, Visvanathan K, Artama M, Vainio H, Pukkala E. Statin use and breast cancer survival: a 
nationwide cohort study from Finland. PLoS One. 2014; 9:e110231. [PubMed: 25329299] 
Narayanan BA, Narayanan NK, Pittman B, Reddy BS. Regression of mouse prostatic intraepithelial 
neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse 
prostate model. Clin Cancer Res. 2004; 10:7727–7737. [PubMed: 15570007] 
Narayanan BA, Narayanan NK, Pttman B, Reddy BS. Adenocarcina of the mouse prostate growth 
inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. 
Prostate. 2006; 66:257–265. [PubMed: 16175586] 
Allott and Hursting Page 27













Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR, Vega GL, Khera A, McGuire DK, 
Grundy SM, et al. Associations of visceral and abdominal subcutaneous adipose tissue with 
markers of cardiac and metabolic risk in obese adults. Obesity (Silver Spring). 2013; 21:E439–
447. [PubMed: 23687099] 
Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan 
PM, Sondhi V, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer 
pathophysiology. Science. 2013; 342:1094–1098. [PubMed: 24288332] 
Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J 
Med. 2012; 367:1792–1802. [PubMed: 23134381] 
Niraula S, Ocana A, Ennis M, Goodwin PJ. Body size and breast cancer prognosis in relation to 
hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat. 2012; 
134:769–781. [PubMed: 22562122] 
Nogueira LM, Dunlap SM, Ford NA, Hursting SD. Calorie restriction and rapamycin inhibit MMTV-
Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity. Endocr Relat 
Cancer. 2012; 19:57–68. [PubMed: 22143497] 
Nunez NP, Perkins SN, Smith NC, Berrigan D, Berendes DM, Varticovski L, Barrett JC, Hursting SD. 
Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr 
Cancer. 2008; 60:534–541. [PubMed: 18584488] 
Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United 
States, 2011-2012. JAMA. 2014; 311:806–814. [PubMed: 24570244] 
Pape-Ansorge KA, Grande JP, Christensen TA, Maihle NJ, Cleary MP. Effect of moderate caloric 
restriction and/or weight cycling on mammary tumor incidence and latency in MMTV-Neu 
female mice. Nutr Cancer. 2002; 44:162–168. [PubMed: 12734063] 
Park HS, Schoenfeld JD, Mailhot RB, Shive M, Hartman RI, Ogembo R, Mucci LA. Statins and 
prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review 
and meta-analysis. Ann Oncol. 2013; 24:1427–1434. [PubMed: 23508824] 
Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM. Clinical outcomes after radical 
prostatectomy in diabetic patients treated with metformin. Urology. 2010; 76:1240–1244. 
[PubMed: 20627287] 
Pelton K, Freeman MR, Solomon KR. Cholesterol and prostate cancer. Curr Opin Pharmacol. 2012; 
12:751–759. [PubMed: 22824430] 
Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Body size and risk of luminal, HER2-
overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol 
Biomarkers Prev. 2008; 17:2078–2086. [PubMed: 18664548] 
Pischon T, Boeing H, Weikert S, Allen N, Key T, Johnsen NF, Tjonneland A, Severinsen MT, 
Overvad K, Rohrmann S, et al. Body size and risk of prostate cancer in the European prospective 
investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2008; 17:3252–3261. 
[PubMed: 18990768] 
Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in 
the PSA era. Int J Cancer. 2008; 123:1693–1698. [PubMed: 18646186] 
Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, 
Thompson IM Jr, Kristal AR. Men with low serum cholesterol have a lower risk of high-grade 
prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol 
Biomarkers Prev. 2009; 18:2807–2813. [PubMed: 19887582] 
Pou KM, Massaro JM, Hoffmann U, Lieb K, Vasan RS, O'Donnell CJ, Fox CS. Patterns of abdominal 
fat distribution: the Framingham Heart Study. Diabetes Care. 2009; 32:481–485. [PubMed: 
19074995] 
Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami HO, 
Sorensen HT. Metformin use and prostate cancer risk. Eur Urol. 2014; 66:1012–1020. [PubMed: 
24857538] 
Renehan AG. Bariatric surgery, weight reduction, and cancer prevention. Lancet Oncol. 2009; 10:640–
641. [PubMed: 19556164] 
Allott and Hursting Page 28













Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a 
systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 
371:569–578. [PubMed: 18280327] 
Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. 
Lancet. 2013; 382:1762–1765. [PubMed: 24268611] 
Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J. Prognostic 
significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002; 
62:632–635. [PubMed: 11830510] 
Robien K, Demark-Wahnefried W, Rock CL. Evidence-based nutrition guidelines for cancer 
survivors: current guidelines, knowledge gaps, and future research directions. J Am Diet Assoc. 
2011; 111:368–375. [PubMed: 21338735] 
Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, Bandera EV, 
Hamilton KK, Grant B, McCullough M, et al. Nutrition and physical activity guidelines for 
cancer survivors. CA Cancer J Clin. 2012; 62:243–274. [PubMed: 22539238] 
Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, Thun MJ, Calle EE. Body 
mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II 
Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2007; 16:63–69. [PubMed: 17179486] 
Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate 
cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol 
Biomarkers Prev. 2001; 10:345–353. [PubMed: 11319175] 
Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol. 1988; 
6:1321–1327. [PubMed: 3411343] 
Rogozina OP, Nkhata KJ, Nagle EJ, Grande JP, Cleary MP. The protective effect of intermittent 
calorie restriction on mammary tumorigenesis is not compromised by consumption of a high fat 
diet during refeeding. Breast Cancer Res Treat. 2013; 138:395–406. [PubMed: 23446811] 
Rosenberg LU, Einarsdottir K, Friman EI, Wedren S, Dickman PW, Hall P, Magnusson C. Risk 
factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol 
Biomarkers Prev. 2006; 15:2482–2488. [PubMed: 17164374] 
Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D, Force 
USPST. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary 
prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services 
Task Force. Ann Intern Med. 2007; 146:376–389. [PubMed: 17339623] 
Roy M, Kung HJ, Ghosh PM. Statins and prostate cancer: role of cholesterol inhibition vs. prevention 
of small GTP-binding proteins. Am J Cancer Res. 2011; 1:542–561. [PubMed: 21984972] 
Rundle AG, Neugut AI. Modeling the effects of obesity and weight gain on PSA velocity. Prostate. 
2009; 69:1573–1578. [PubMed: 19562734] 
Scales CD Jr, Curtis LH, Norris RD, Schulman KA, Dahm P, Moul JW. Relationship between body 
mass index and prostate cancer screening in the United States. J Urol. 2007; 177:493–498. 
[PubMed: 17222617] 
Schmitz KH, Neuhouser ML, Agurs-Collins T, Zanetti KA, Cadmus-Bertram L, Dean LT, Drake BF. 
Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity. J Natl 
Cancer Inst. 2013; 105:1344–1354. [PubMed: 23990667] 
Scosyrev E, Tobis S, Donsky H, Wu G, Joseph J, Rashid H, Messing E. Statin use and the risk of 
biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight 
cohort studies. BJU Int. 2013; 111:E71–77. [PubMed: 23017100] 
Shafique K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS. Cholesterol and the risk of grade-
specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 
37 years' follow up. BMC Cancer. 2012; 12:25. [PubMed: 22260413] 
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5–29. [PubMed: 
25559415] 
Sjostrom L, Gummesson A, Sjostrom CD, Narbro K, Peltonen M, Wedel H, Bengtsson C, Bouchard 
C, Carlsson B, Dahlgren S, et al. Effects of bariatric surgery on cancer incidence in obese 
patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. 
Lancet Oncol. 2009; 10:653–662. [PubMed: 19556163] 
Allott and Hursting Page 29













Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard 
C, Carlsson B, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J 
Med. 2007; 357:741–752. [PubMed: 17715408] 
Smith MR. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for 
prostate cancer. Clin Cancer Res. 2007; 13:241–245. [PubMed: 17200361] 
Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, 
Sledge GW Jr, et al. Obesity at diagnosis is associated with inferior outcomes in hormone 
receptor-positive operable breast cancer. Cancer. 2012; 118:5937–5946. [PubMed: 22926690] 
Srokowski TP, Fang S, Hortobagyi GN, Giordano SH. Impact of diabetes mellitus on complications 
and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol. 2009; 
27:2170–2176. [PubMed: 19307509] 
Stevens GA, Singh GM, Lu Y, Danaei G, Lin JK, Finucane MM, Bahalim AN, McIntire RK, Gutierrez 
HR, Cowan M, et al. National, regional, and global trends in adult overweight and obesity 
prevalences. Popul Health Metr. 2012; 10:22. [PubMed: 23167948] 
Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, Kopelovich L, Hudis CA, 
Dannenberg AJ. Increased levels of COX-2 and prostaglandin E2 contribute to elevated 
aromatase expression in inflamed breast tissue of obese women. Cancer Discov. 2012; 2:356–
365. [PubMed: 22576212] 
Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/
neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem. 2002; 
277:18649–18657. [PubMed: 11901151] 
Suissa S, Azoulay L. Metformin and the Risk of Cancer: Time-related biases in observational studies. 
Diabetes Care. 2012; 35:2665–2673. [PubMed: 23173135] 
Sundaram S, Freemerman AJ, Galanko JA, McNaughton KK, Bendt KM, Darr DB, Troester MA, 
Makowski L. Obesity-mediated regulation of HGF/c-Met is associated with reduced basal-like 
breast cancer latency in parous mice. PLoS One. 2014a; 9:e111394. [PubMed: 25354395] 
Sundaram S, Freemerman AJ, Johnson AR, Milner JJ, McNaughton KK, Galanko JA, Bendt KM, Darr 
DB, Perou CM, Troester MA, et al. Role of HGF in obesity-associated tumorigenesis: C3(1)-
TAg mice as a model for human basal-like breast cancer. Breast Cancer Res Treat. 2013; 
142:489–503. [PubMed: 24218051] 
Sundaram S, Le TL, Essaid L, Freemerman AJ, Huang MJ, Galanko JA, McNaughton KK, Bendt KM, 
Darr DB, Troester MA, et al. Weight Loss Reversed Obesity-Induced HGF/c-Met Pathway and 
Basal-Like Breast Cancer Progression. Front Oncol. 2014b; 4:175. [PubMed: 25072025] 
Suzuki R, Orsini N, Saji S, Key TJ, Wolk A. Body weight and incidence of breast cancer defined by 
estrogen and progesterone receptor status--a meta-analysis. Int J Cancer. 2009; 124:698–712. 
[PubMed: 18988226] 
Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX. Body mass index, diabetes, and triple-negative 
breast cancer prognosis. Breast Cancer Res Treat. 2014; 146:189–197. [PubMed: 24869799] 
Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, 
Dannenberg AJ, Neugut AI. Association of frequency and duration of aspirin use and hormone 
receptor status with breast cancer risk. JAMA. 2004; 291:2433–2440. [PubMed: 15161893] 
Thomas JA 2nd, Antonelli JA, Lloyd JC, Masko EM, Poulton SH, Phillips TE, Pollak M, Freedland 
SJ. Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. Prostate 
Cancer Prostatic Dis. 2010; 13:350–355. [PubMed: 20733612] 
Thompson HJ, McTiernan A. Weight cycling and cancer: weighing the evidence of intermittent caloric 
restriction and cancer risk. Cancer Prev Res (Phila). 2011; 4:1736–1742. [PubMed: 21982873] 
Thompson MD, Grubbs CJ, Bode AM, Reid JM, McGovern R, Bernard PS, Stijleman IJ, Green JE, 
Bennett C, Juliana MM, et al. Lack of effect of metformin on mammary carcinogenesis in 
nondiabetic rat and mouse models. Cancer Prev Res (Phila). 2015; 8:231–239. [PubMed: 
25681088] 
Togawa K, Ma H, Sullivan-Halley J, Neuhouser ML, Imayama I, Baumgartner KB, Smith AW, Alfano 
CM, McTiernan A, Ballard-Barbash R, et al. Risk factors for self-reported arm lymphedema 
among female breast cancer survivors: a prospective cohort study. Breast Cancer Res. 2014; 
16:414. [PubMed: 25145603] 
Allott and Hursting Page 30













Tsai H, Keating NL, Van Den Eeden SK, Haque R, Cassidy-Bushrow AE, Yood MU, Smith MR, 
Potosky AL. Risk of Diabetes among Patients Receiving Primary Androgen Deprivation Therapy 
for Clinically Localized Prostate Cancer. J Urol. 2014; 193:1956–1962. [PubMed: 25524243] 
Tsilidis KK, Allen NE, Appleby PN, Rohrmann S, Nothlings U, Arriola L, Gunter MJ, Chajes V, 
Rinaldi S, Romieu I, et al. Diabetes mellitus and risk of prostate cancer in the European 
Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2015a; 136:372–381. 
[PubMed: 24862312] 
Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K, Sacerdote C, Ashby 
D, Vineis P, Tzoulaki I, et al. Metformin does not affect cancer risk: a cohort study in the U.K. 
Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care. 2014; 
37:2522–2532. [PubMed: 24898303] 
Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella 
review of meta-analyses of observational studies. BMJ. 2015b; 35010.1136/bmj.g7607
Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational 
studies. Breast Cancer Res Treat. 2012; 135:261–269. [PubMed: 22806241] 
Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses 
HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in 
human breast carcinoma cells. Cell Cycle. 2009; 8:88–96. [PubMed: 19106626] 
Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Adriole GL, Freedland SJ. Aspirin, 
NSAID and risk of prostate cancer: Results from the REDUCE study. Clin Cancer Res. 2014; 
15:756–762. [PubMed: 25520389] 
Vrieling A, Buck K, Kaaks R, Chang-Claude J. Adult weight gain in relation to breast cancer risk by 
estrogen and progesterone receptor status: a meta-analysis. Breast Cancer Res Treat. 2010; 
123:641–649. [PubMed: 20711809] 
Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010; 10:181–193. [PubMed: 
20168319] 
Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson 
PS, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic 
prostate cancer. Cancer Cell. 2003; 4:209–221. [PubMed: 14522255] 
Wang X, Lin YW, Wu J, Zhu Y, Xu XL, Xu X, Liang Z, Hu ZH, Li SQ, Zheng XY, et al. Meta-
analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk. World J Surg 
Oncol. 2014; 12:304. [PubMed: 25282624] 
Whitley BM, Moreira DM, Thomas JA, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL, 
Freedland SJ. Preoperative weight change and risk of adverse outcome following radical 
prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. 
Prostate Cancer Prostatic Dis. 2011; 14:361–366. [PubMed: 21894174] 
Woditschka S, Haag JD, Mau B, Lubet RA, Gould MN. Chemopreventive effects of celecoxib are 
limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model. 
Breast Cancer Res. 2008; 10:R18. [PubMed: 18279516] 
Wolters R, Schwentner L, Regierer A, Wischnewsky M, Kreienberg R, Wockel A. Endocrine therapy 
in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle. 
Breast Cancer Res Treat. 2012; 131:925–931. [PubMed: 22080246] 
World Cancer Research Fund / American Institute for Cancer Research. Food, Nutrition, Physical 
Activity, and the Prevention of Cancer: a Global Perspective. Washington DC: AICR; 2007. 
Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a 
population-based case-control study. Cancer Causes Control. 2009; 20:1617–1622. [PubMed: 
19653109] 
Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, Hurwitz P, Hollenbeck A, 
Leitzmann MF. Prospective study of adiposity and weight change in relation to prostate cancer 
incidence and mortality. Cancer. 2007; 109:675–684. [PubMed: 17211863] 
Wu C, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL, Freedland SJ. Diabetes predicts 
metastasis after radical prostatectomy in obese men: results from the SEARCH database. BJU 
Int. 2013; 111:E310–318. [PubMed: 23305170] 
Allott and Hursting Page 31













Xu H, Hu MB, Bai PD, Zhu WH, Ding Q, Jiang HW. Will metformin postpone high-fat diet 
promotion of TRAMP mouse prostate cancer development and progression? Int Urol Nephrol. 
2014; 46:2327–2334. [PubMed: 25158895] 
Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, 
Broeks A, Cox A, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled 
analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011; 
103:250–263. [PubMed: 21191117] 
Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T, Wada 
S. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer. 2000; 89:589–596. [PubMed: 
10931458] 
Yu H, Yin L, Jiang X, Sun X, Wu J, Tian H, Gao X, He X. Effect of metformin on cancer risk and 
treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies. 
PLoS One. 2014a; 9:e116327. [PubMed: 25545701] 
Yu O, Eberg M, Benayoun S, Aprikian A, Batist G, Suissa S, Azoulay L. Use of statins and the risk of 
death in patients with prostate cancer. J Clin Oncol. 2014b; 32:5–11. [PubMed: 24190110] 
Zhang F, Yang Y, Skrip L, Hu D, Wang Y, Wong C, Qiu J, Lei H. Diabetes mellitus and risk of 
prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies. Acta 
Diabetol. 2012; 49:S235–246. [PubMed: 23124624] 
Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and 
mortality: a meta-analysis. Cancer Epidemiol. 2013; 37:207–218. [PubMed: 23352629] 
Zhang X, Zhou G, Sun B, Zhao G, Liu D, Sun J, Liu C, Guo H. Impact of obesity upon prostate 
cancer-associated mortality: A meta-analysis of 17 cohort studies. Oncol Lett. 2015; 9:1307–
1312. [PubMed: 25663903] 
Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor 
is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 
(aromatase) gene. Endocrinology. 1996; 137:5739–5742. [PubMed: 8940410] 
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi 
N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism 
of metformin action. J Clin Invest. 2001; 108:1167–1174. [PubMed: 11602624] 
Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR. Cholesterol-rich lipid rafts mediate akt-
regulated survival in prostate cancer cells. Cancer Res. 2002; 62:2227–2231. [PubMed: 
11956073] 
Allott and Hursting Page 32














Using a transdisciplinary approach to study mechanisms linking obesity and cancer.
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Non-biologic mechanisms linking obesity and cancer mortality.
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Putative mechanisms linking obesity with cancer risk and progression: lessons from studies 
of chemopreventive agents
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Computed tomography (CT) scans of two individuals with similar waist circumference 
(WC) but different amounts of visceral and subcutaneous fat area, illustrating the potential 
for misclassification when using WC as a surrogate of visceral obesity.
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Challenges associated with studying obesity: defining the exposure, and potential 
confounders.
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